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ABSTRACT 
Background of the study:  
Recurrent Aphthous Stomatitis is a chronic inflammatory ulcerative, relapsing, 
remitting oral mucosal disease affecting 50% of the population, with three classic 
forms namely minor, major and Herpetiform types. Despite numerous studies, the 
exact etiology of RAS has not been described, but the abnormality in Host factors and 
environmental factors have been implicated. Hematinic deficiency (Serum Ferritin and 
Serum Vitamin B12) in particular was found to be twice as common. Although  the 
mechanism of  RAS  is  not fully understood,  Many investigators noticed lower 
prevalence rate of RAS in smokers when compared to nonsmokers, increase in  the  
incidence of RAS  following  smoking  cessation,  and resolution of  lesions upon 
resumption of  cigarettes smoking. Cotinine is the major degradation product of 
nicotine metabolism and it can be assayed in various biological Fluids. Due to its 
relatively longer half-life in circulation, Cotinine is used as a most common biomarker 
used to assess nicotine exposure and abstinence.  In the present study, cotinine level 
has been assessed in plasma, because plasma cotinine concentration is highly 
correlated with tobacco smoke exposure from both direct smoke inhalation via 
cigarette consumption and environment exposure via secondhand smoke.  
Aims: 
 To compare the level of Plasma Cotinine, Serum B12 and Serum Ferritin to 
enlighten the etiological factor of Recurrent Aphthous Stomatitis. 
 To assess whether the Plasma Cotinine levels have a positive influence in 
Recurrent Aphthous Stomatitis and to determine the role of Serum Ferritin 
and Serum Vitamin B12 in Recurrent Aphthous Stomatitis Versus Controls.  
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Materials and Method: 
Haematological investigations of Plasma Cotinine, Serum Vit.B12 and Serum 
Ferritin levels were evaluated among smokers and nonsmokers in patients with 
Recurrent Aphthous Stomatitis from the Department of Oral Medicine and Radiology, 
to check for the prevalence of RAS and also the influence of Plasma Cotinine, Serum 
Ferritin and Serum Vit.B12 in the etiopathogenesis of RAS. The study population 
comprises of 40 patients, divided into 4 groups, of which 10 in each group, were 
Group 1-Healthy patients, Group 2- Patients with Recurrent Aphthous Stomatitis, 
Group 3-Smokers without RAS, Group 4-Smokers with RAS. After getting informed 
consent from each patients ,3ml of blood Samples were collected and analysed for 
Plasma Cotinine levels by using 96 well MicroPlate Cotinine-Specific- Enzyme 
Linked Immunosorbent Assay method and Serum Vit.B12 and  Ferritin levels using 
Chemiluminescent Assay Method. The data was analysed by Statistical package of 
Social Sciences (SPSS16.0).ANOVA followed by Dunnet t test was applied to find 
the Statistical Significance between the groups. 
Results:  
  Our study reveals that, analysis of the Plasma Cotinine level among the 4 
groups showed a significant rise in Plasma Cotinine level among smokers and 
reduced levels among RAS patients, be it smoker or nonsmoker. Our evaluation of 
Serum vitaminB12 and Ferritin among the 4 groups revealed that patients with RAS 
has significantly low levels whereas smokers without RAS had elevated levels 
.Smokers with RAS had reduced levels of Vit.B12 and Ferritin when compared to 
Smokers without RAS. From a broader perspective our study reiterates the fact that 
RAS was more prevalent among females and showed increased incidences in 
individual who stopped smoking habit.  
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Conclusion:  
Knowledge from the study suggest that, pure nicotine (not the other 
components of tobacco) is a safe component, although it depends on the dose. 
Tilldate, tobacco has had only a prophylactic role against aphthous ulcers, therefore 
the role of inundated nicotine in tobacco as a beneficial factor should be taken in to 
account. The present study sheds light on the importance of investigating Serum 
Ferritin and Vit.B12 in patients with RAS and also shows the need for close 
supervision regarding the dietary intake of Iron and nutritional supplements, 
especially Vitamin B12 in such patients. The study also reveals the fact that the 
prevalence of RAS is high among patients with recent cessation of smoking habits, 
therefore Nicotine Replacement Therapy must be investigated as a therapeutic 
option for RAS patients. 
Keywords:  Cotinine, Ferritin, Nicotine, Sutton Disease, Vitamin B12  
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INTRODUCTION 
The term aphthae  is derived from the Greek word aphthi, which means “to 
set on fire “or “to inflame” and  is described  by  Great philosopher Hippocrates as 
pain associated with a common disorder of  oral mucosa during his time (Recurrent 
Aphthous Stomatitis).1  Recurrent Aphthous Stomatitis  is a chronic inflammatory  
ulcerative,  relapsing,  remitting oral mucosal disease affecting 50% of the 
population, with three classic forms namely minor,  major and Herpetiform types. 
These subtypes vary with respect to morphologic, distribution, severity and 
prognosis.2,3 
Despite numerous studies, the exact etiology of RAS has not been described, 
but the abnormality in Host factors such as Genetic, Immunological, 
Haematological, Vitamin deficiency, Physical or Emotional stress and 
environmental factors such as microtrauma, chemical injury and infections have 
been implicated. Hematinic deficiency (Serum Ferritin and Serum Vitamin B12) in 
particular  was found to be twice as common.4 Although  the mechanism of  RAS  is  
not fully understood,  Many investigators observed lower prevalence rate of RAS in 
smokers when compared to nonsmokers, increase in  the incidence of RAS  
following the termination of smoking  ,  and resolution of  lesions upon restarting of  
cigarettes smoking.5-14 
 Cotinine is the major degradation product of nicotine metabolism and it can 
be assayed in various biological Fluids (Including Plasma, Serum, Saliva, Urine, 
and Semen). Due to its relatively longer half-life in circulation, Cotinine is used as 
a most common biomarker used to assess nicotine exposure and abstinence. At the 
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same time, Cotinine testing provides a more accurate measure than exhaled air 
Carbon monoxide, one of the most widely used biomarkers in smoking research 
and has proved to be more desirable in examining nicotine intake due to its ability 
to determine tobacco smoke exposure over a longer time frame than CO 
monitoring.15,16 
In the present study, cotinine level has been assessed in plasma, because 
plasma cotinine concentration is highly associated with tobacco smoke exposure 
from both direct smoke inhalation via cigarette depletion and environment exposure 
via secondhand smoke. 17-20 Number of studies have reported that pure nicotine(not 
the other components of tobacco) is a safe component, although it depends on the 
dose.21,22 Until date, tobacco has had only a preventative role against aphthous ulcers 
,therefore the role of inundated nicotine in tobacco as a therapeutic factor should be 
taken in to account.23 
At the same time, there are two probable theories regarding the preventive 
effect of smoking on RAS has been reported: 
 Cigarette smoking prevents aphthous ulcers by causing an increase in 
localized keratinization of the oral mucosa.23 
 Nicotine via several possible mechanisms could modulate local immune 
responses as it has been shown to induce T-Cells anergy and inhibits the 
production of proinflammatory cytokines, such as interleukin(IL-2,IL-
6,IL-8,IL-10) and tumor necrosis factor α.  It can also activate the release 
of adrenocorticotrophic hormone and cortisol, thereby leading of further 
suppression of inflammatory pathways.24 
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 Cotinine Levels in Plasma increases with increase in cigarette smoke 
exposure. The blood Plasma Cotinine level that is accepted as defining a smoker is a 
level > 25 ng ml-1. Levels above 25 ng ml-1 correlate well with the number of 
cigarettes smoked per day. Cotinine Levels between 0 and 25 ng ml-1 occur in 
individuals exposed to cigarette smoke passively .8 
 Assessment of Plasma Cotinine level should be done within 24hrs, after 
smoking. According to Centre for Disease Control and Prevention, Smokers are 
classified as: 
 Current Smokers - Smoked   ≥ 100 cigarettes over their lifetime and smoked   
atleast 10 hrs before the time of interview. 
 Never Smoker   -   Never smoked any cigarettes in their lifetime. 
 Former Smoker -  Smoked  ≥ 100 cigarettes over their lifetime and were not 
smoking at the time of interview or 24hrs prior to the interview.25 
 Many studies have suggested that haematinic deficiency of Serum B12 and 
serum Ferritin were twice as common in patient with Recurrent Aphthous 
Stomatitis. Ferritin is a globular protein which exist intracellularly in which iron is 
aggregated in a soluble non-toxic form. Basically, Ferritin in the serum is highly 
affiliated with iron stores in the body. Serum Ferritin determination provides direct 
measurement of total body iron store and thus helps in the differentiation between 
Iron deficiency aneamia and aneamia due to chronic infections.26,27 
Serum B12 is demonstrated to be the most frequently found haematinic 
deficiency which suppresses the cell mediated immunity and causes changes in the 
epithelium of tongue and the buccal mucosa. Serum B12 is also essential for the 
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synthesis of DNA and its deficiency results in the development of megaloblastic 
anaemia.28 
Hence, the present study is carried out to compare the level of Plasma 
Cotinine, Serum B12 And Serum Ferritin to enlighten the etiological factor of 
Recurrent Aphthous Stomatitis as well as to assess whether the Plasma Cotinine 
levels have a positive influence in Recurrent Aphthous Stomatitis and to determine 
the role of Serum Ferritin and Serum Vitamin B12 in Recurrent Aphthous Stomatitis 
Versus Controls. In essence we embark on a journey to find if there is any positiver 
from the oft disreputed smoking habit. 
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AIMS 
 To compare the level of Plasma Cotinine, Serum B12 and Serum Ferritin to 
enlighten the etiological factor of Recurrent Aphthous Stomatitis. 
 To assess whether the Plasma Cotinine levels have a positive influence in 
Recurrent Aphthous Stomatitis and to determine the role of Serum Ferritin and 
Serum Vitamin B12 in Recurrent Aphthous Stomatitis Versus Controls.  
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REVIEW OF LITERATURE 
BASIC PARAMETERS ANALYSED IN THE STUDY:  
1. COTININE  
Nicotine, the foremost addictive compound in tobacco, is metabolized 
principally by the hepatic enzyme CYP2A6 to cotinine (COT) and then exclusively by 
CYP2A6 to 3′-hydroxycotinine (3HC). The gene encoding this enzyme is supremely 
polymorphic, resulting in large difference in rates of nicotine metabolic inactivation. 
Because of the main role that CYP2A6 plays in nicotine’s metabolism,   any genetic 
variation in CYP2A6 alters total nicotine clearance, non-renal plasma clearance, and 
nicotine plasma half-life. Genetically slow metabolizers are less prone to be a 
smokers; those who are smokers are less vulnerable and smoke fewer cigarettes per 
day. COT has a long half-life (averaging 16 h), making its assessment a relatively 
powerful indicator of the “time to last cigarette.” By comparison, 3HC has a longer 
half-life (averaging 5 h). Among regular smokers, because levels of COT reach 
equilibrium state, the elimination of 3HC is CYP2A6 formation-dependent, and the 
NMR ratio is stable over time. The NMR can be evaluated in the saliva, urine, or 
plasma of smokers and has been validated as a biomarker of nicotine clearance. New 
data on the reproducibility and authenticity of the NMR are developing.29 
Nicotine is a tertiary amine made up of a pyridine and a pyrrolidine ring. (S)-
nicotine, found in tobacco, binds up stereoselectively to nicotinic cholinergic receptors 
(nAChRs). (R)-nicotine, found in minute quantities in cigarette smoke undergoes 
racemization during the pyrolysis process, is a weak agonist at nAChRs. When a 
person inhales smoke from a cigarette, nicotine is filtered from the tobacco and is 
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moved through smoke particles into the lungs, where it is absorbed rapidly into the 
pulmonary venous circulation. It then enters the arterial circulation and moves rapidly 
to the brain. Nicotine diffuses easily into brain tissue, where it binds to nAChRs, 
which are ligand-gated ion channels. When a cholinergic agonist attach to the outside 
of the channel, the channel opens, and permits the entry of sodium and calcium. These 
cations activate voltage-dependent calcium channels, and allows more calcium entry. 
The nAChR complex composed of five subunits and is found in both the peripheral 
and central nervous systems .Activation of central nAChRs by nicotine results in the 
release of a variety of neurotransmitters in the brain, most importantly dopamine.30 
Nicotine is a tobacco-speciﬁc biomarker. Nicotine is primarily metabolized to 
cotinine in the liver, either in particle or vapour phase, nicotine when absorbed the 
half-life in body fluids is approximately 2–3 hr, while cotinine is 12–20 hr. Because of 
its long half-life, cotinine, can be measured in saliva, urine, on exposure to tobacco he 
widely used biomarker is Plasma or serum. . Cotinine levels can be evaluated in the 
laboratory by radioimmunoassay, gas-liquid chromatography or liquid chromatography 
method  in many different body constituents, including blood, urine, saliva, amniotic 
fluid cervical mucus, and hair. Cotinine remains the objective index for tobacco-derived 
carcinogen exposure. Cotinine is used for its individual variability in self-reported 
cigarettes smoked per day and on exposure to tobacco-derived carcinogen 
systemically. Increased lung cancer risk have been mainly associated with higher 
plasma cotinine levels.  Six primary metabolites of cotinine in humans are namely: 3′-
hydroxycotinine, 5′-hydroxycotinine, which reside in tautomeric equilibrium with the 
open chain derivative 4-oxo-4-(3-pyridyl)-N-methylbutanamide, cotinine N-oxide, 
cotinine glucuronide, cotinine methonium ion,  and norcotinine.31 
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SERUM VITAMIN B12  
(SYNONYMS - Anti Pernicious anaemia factor, Extrinsic Factor of Castle, 
Animal Protein Factor, cyanocobalamine) 
The term “vitamin B12” is used as a generic descriptor for the cobalamins - 
those corrinoids (cobalt containing compounds possessing the corrinring) having the 
biologic activity of the vitamin. Some corrinoids that are growth factors for 
microorganisms, not only have vitamin B12 activity but may also be antimetabolites 
of the vitamin. Although it is synthesized purely by microorganisms, but its sources 
are found in animal foods, there being no plant sources for this vitamin. This means 
that strict vegetarians (vegans) are at risk of developing B12 deficiency.  
        Vitamin B12 Absorption Requires Two Binding Proteins - Vitamin B12 is 
absorbed bound to intrinsic factor, a small glycoprotein secreted by the parietal cells 
of the gastric mucosa. Gastric acid and pepsin release vitamin from protein binding 
in food and make it available to bind to cobalophilin, a binding protein secreted in 
the saliva. In the duodenum, cobalophilin is hydrolyzed, releasing the vitamin for 
binding to intrinsic factor. Pancreatic insufficiency can therefore be a factor in the 
development of vitamin B12 deficiency, resulting in the excretion of cobalophilin-
bound vitamin B12. Intrinsic factor binds the various vitamin B12 vitamers, but not 
other corrinoids. Vitamin B12 is also absorbed from the distal third of the ileum via 
receptors that bind the intrinsic factor-vitamin B12 complex but not free intrinsic 
factor or free vitamin. 32 
Vitamin B12 is water soluble, heat stable and red in color. It holds 4.35% 
cobalt by weight. The empirical formula is C63H88N14P1CO1. Four pyrrole ring 
coordinated with a cobalt atom is called a Corrin ring. The 5th valency of the cobalt 
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atom is covalently linked at right angles to a substituted benzimidazole ring, called 
Cobalamin. The 6thvalency of the cobalt is satisfied by any of the following groups: 
Cyanide, hydroxyl, adenosyl or methyl. When cyanide is added at the Rth position, 
the molecule is called cyanacobalamin. During the isolation procedure, cyanide is 
added to get stable crystals. The CN group has no physiological function. However 
common drug preparation for oral are in this form. When hydroxyl group is attached 
at the R th position is called hydroxyl cobalamin and injectable preparation are in 
this form. It is also known as B12a. Both forms, when taken up by the cells these 
group are removed and deoxyadenosylcobalamin are synthesized. When the 
adenosyl group is replaced by methyl group it is known as methyl cobalamin. This is 
the major one, present in blood circulation as well as in cytoplasm of cell.33 
In 1948, it was observed that certain animal proteins contains a “growth 
factor” which is not present in vegetable foods nor yeasts. This was termed as 
“animal protein factor”(APF).In 1948,a red crystalline substance was isolated from 
Liver which produced clinical emissions in “Pernicious anaemia” and it was called 
as “antipernicious anaemia factor” .The same substance was isolated from cultures 
of several microorganisms, found to possess “animal growth factor activity’’. The 
substance was   named as vitamin B12.A number of closely related substances occur 
in nature possessing varying degree of vitamin B12 activity. Later these substance 
was also named as “extrinsic factor of castle”. Chemistry- a) Structure of 
VitaminB12 - The central portion of the molecule consists of four reduced and 
extensively substituted “pyrrole rings”, surrounding a single cobalt atom (CO). This 
central structure is called as “Corrin Ring” system. This corrin ring system is similar 
to porphyrins, but differ in that two of pyrrole rings. Rings I and IV are joined 
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directly. Below the corrin ring system is DBI ring -5, 6- dimethyl Benzimidazole 
riboside which is connected, at one end, to central cobalt atom, and at the other end 
from the riboside moiety to the ring IV of corrin ring system. One PO4 group 
connects ribose moiety to “aminopropanol” which in turn is connected to propionic 
acid side chain of ring IV. If Cyanide group is bound to the cobalt atom and then it 
is alsoncalled as “cyanide cobalamine”. Normal Serum Level vitamin B12 - 0.008- 
0.42µg/dl (Average = 0.02 µg/dl). Storage - Main storage site is Liver.34 
SERUM FERRITIN 
Iron is an essential element in humans. There are 50-70 mmol(3-1g) of iron 
in the body. Three-quarters are present as the molecular complex with haem. Most 
of the remaining iron, tissue stores bound to the iron storage proteins, ferritin and 
haemosiderin. Less than one percent of total body iron is in the plasma, where it is 
associated with the iron-binding protein, transferrin. Body iron is efficiently 
reutililed. Dietary intake is about 0.35 mmol (20 mg per day). Iron is transported in 
plasma bound to the specific glycoprotein, transferrin, each molecule of which binds 
two Fe" ion together with bicarbonate as an anion. A number of factors can lower 
serum iron independently of iron status. Serum iron determination are of limited 
routine value being of most assistance in the diagnosis of iron overload and acute 
iron poisoning. Total iron binding capacity (TlBC) of a serum specimen is, an 
indirect measure of transferrin concentration. Serum ferritin is the best indicator of 
body iron stores. It is, normally greater than 12 µg/l.  The acute phase response to 
infection. Injury or malignant diseases result in increases in serum ferritin level.35 
Iron is mainly absorbed in the stomach and duodenum. In normal people, 
about 10% of dietary iron is usually absorbed. However, in iron deficit individuals 
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and growing children, a much higher proportion of dietary iron is absorbed to meet 
the increased body demands. Iron is mostly present in the foods in ferric form, 
bound to proteins or organic acids. In the acidic medium provided by gastric HCL, 
the fe3+ is released from foods. Reducing substances such as ascorbic acid and 
Cysteine convert ferric form to   ferrous form. Iron in the ferrous form is soluble and 
readily absorbed. Iron in the mucosal cells by absorption is oxidized to ferric form 
by the enzyme ferroxidase.Fe3+ then combines with apoferritin to form ferritin, 
which is the temporary form storage form of iron. From the mucosal cells, iron may 
enter the blood stream or lost when the cells are desquamated. Iron is stored mainly 
in Liver, spleen and bone marrow in the form of ferritin. In the mucosal cells, Iron is 
stored in, temporary storage form. The maximum iron content of ferritin on weight 
basis is around 5%.36 
Total body iron content is 3 to 5gm; 75% of which is in blood, the rest is in 
liver, bone marrow and muscles. Iron is present in almost all cells. Blood contains 
14.5g of Hb per 100ml.About 75% of total iron is in Haemoglobin and 5% is in 
myoglobin and 15% in ferritin. Iron is absorbed by upper part of duodeunum. The 
following factors affects the absorption of iron. A) Reduced form of Iron-only 
ferrous form is absorbed .Ferric form is not absorbed. B) Ascorbic Acid- Ferric ions 
are reduced with the help of gastric Hcl, ascorbic acid, Cysteine and SH groups of 
proteins.37 
Challacombe SJ and his associates in 1983 conducted a study comprised of 
301 subjects (223 patients and 78 controls), sensitive radioassay for ferritin was 
developed and which was used to examine serum ferritin levels in 105 patients with 
recurrent oral ulceration (ROU), 41 patients with Behcet's syndrome (BS), 42 with 
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other ulcerative oral lesions, 35 patients with non-ulcerative oral lesions and 78 
controls. The prevalence of low serum ferritin levels was  found to be 8% in patients 
with ROU, 15% in BS and 9.5% in patients with other ulcerative oral lesions, 
whereas  less than 3% in patients with non-ulcerative oral disorders and in controls. 
It has been reported that in a small number of patients, oral ulceration may be an 
initial presenting sign of iron deficiency and ROU already present will be 
aggravated by concurrent iron deficiency. Therefore, results of this study suggested 
that serum ferritin levels are a useful part of the haematological investigations in 
patients with ROU rather than serum iron, since it appears to distinguish between 
patients with true iron deficiency and those with secondary sideropenia which is a 
part of the haematological investigations in patients with ROU.38 
Hill P, Haley NJ and Wynder EL in 1983 conducted a cross sectional 
investigation in 450 smokers to determine (a) whether blood levels of 
carboxyhemoglobin, thiocyanate, nicotine and cotinine correlated with self-reported 
consumption of cigarettes and relative yields of selected brands; (b) whether a dose 
dependent increase in smoke constituent absorption occurred; (c) whether 
compensation occurred in individuals smoking different brands. Since plasma nicotine 
has a short half-life, 30-80 min, validation of plasma nicotine levels depends on the 
time elapsed since the last cigarette smoked. All smokers had a cigarette during the 90 
min prior to the study, but none had smoked during the 30 min prior to venipuncture. 
Blood samples were analysed for carboxyhemoglobin spectrophotometrically using an 
IL-182 Co-oximeter. Following carboxyhemoglobin analysis, the blood was 
centrifuged and the plasma frozen at -20°C until assayed. Plasma nicotine and cotinine 
were analysed by radioimmunoassay (RIA) as described by Langone et al. Plasma 
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thiocyanate was determined by the method of Butts et al. A progress of plasma 
nicotine and cotinine concentration at levels above 20 cigarettes per day with a steady 
increase of carboxyhemoglobin and thiocyanate with increasing consumption of 
cigarettes occurred. Smoking cigarettes yielding more or less than I mg nicotine 
conveyed that smokers of low yield brands had decreased plasma levels of nicotine 
and cotinine, but comparable levels of carboxyhemoglobin and thiocyanate. Despite 
the lesser nicotine yield of cigarettes, certain modification in smoking behaviour 
empowered the smoker to acquire as much carbon monoxide and thiocyanate 
constituents from low and high yield cigarettes; thus counteracting the advantage of 
low nicotine yield brands.39 
In 1988, Wall MA, Johnson J, Jacob P and Benowitz LN done a study on 
Ninety-eight subjects comprised of 28 nonsmokers (NS) who neither lived with 
smokers nor worked in an environment where smoking was allowed, 20 passive 
smokers (PS) who did not smoke but either lived with a smoker (n = 8) or worked in 
an office or ward where smoking was allowed, and 49 active smokers (AS) who 
smoked three to 50 cigarettes per day. After getting Informed consent from each 
subjects, Cotinine assay was performed in a blinded fashion using gas liquid 
chromatography. Urine creatinine level was analysed using standard methodology. 
Results of this study suggested that only a minority of nonsmokers had detectable 
levels of cotinine in their serum or saliva. Similarly, cotinine was only detectable in 
the serum of eight passive smokers and in the saliva of five. All 49 active smokers 
had detectable levels of cotinine in their serum and 45 of the AS had cotinine in 
saliva. Datas from this study and those of previous investigators indicated that 
measurement of cotinine in serum, saliva, or urine can separate out active smokers 
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from nonsmokers and passive smokers with high accuracy. Among active smokers, 
there was relatively high degree of intersubject variability of cotinine levels among 
subjects claiming to smoke the same number of cigarettes per day, although light 
smokers had considerably lower mean levels than heavier smokers.40 
Martin J and his associates in 1988 done a comparative study on Cotinine 
elimination from plasma, saliva, and urine. The total sample size was 5 subjects, 
who were volunteers from the staff of the Addiction Research Unit. Out of which 
one had never smoked, two were ex-cigarette smokers, and two were current 
smokers. All subjects abstained from smoking over the period of the study. The 
study procedure required the subjects to develop a high body cotinine level  via the  
ingestion of  28mg nicotine base per day  over  five-day period in order to bring  
cotinine concentrations similar to those from smoking and then to cease nicotine 
intake while cotinine elimination was followed over an 11-day period.  Extensive 
first pass metabolism ensure conversion of nicotine with only minute amounts of 
unchanged cotinine entering the systemic circulation. Then the specimens collected 
from different body fluids were assayed for cotinine independently by two 
laboratories using gas chromatographic methods. And he reported that, following the 
period of nicotine ingestion, mean concentrations of cotinine were 350 ng/ml in 
saliva, 294 ng/ml in plasma and 1394 ng/ml in urine, as values similar to those 
found in smokers. Then the cotinine concentration declined to nonsmoking values in 
all fluids by Day 4 (< 10 ng/ml in plasma and saliva and < 50 ng/ml in urine). And 
the average ratios of cotinine concentration in saliva to plasma were found to be 
1.15ng/ml and 0.97ng/ml. And he concluded that there was no significant difference 
in cotinine concentration of blood, saliva and urine. And also they reported that, the 
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choice of body fluids serve as a primordial factor for cotinine assay determination 
should be taken as consideration in smoking studies rather than practical or 
pharmacokinetic considerations.41 
Etzel RA in 1990 found out that Cotinine, the major degradation product of 
nicotine metabolism, serves as useful marker for exposure to tobacco smoke and it 
can be measured in plasma, serum, or saliva. The study was conducted, for assessing 
the relationship between cotinine concentration in saliva and self-reported tobacco 
smoke consumption in active and passive smokers, an English-language literature 
search using MEDLINE was being organized (1973-1989), and the bibliographies 
were reviewed. In total of 43 original studies conducted, inclusion criteria was met 
by 22 studies, where relative information regarding population studies, exposure to 
smoked tobacco, estimating methods, and concentrations of cotinine was evaluated. 
Reviews affirms that passive smokers  have cotinine concentrations below 5ng/ml in 
case of saliva whereas  heavy passive exposure have  310 ng/ml. Levels between 10 
and 100 ng/ml may result from unusual active smoking or regular active smoking 
with low nicotine intake. Levels >l00ng/ml are probably the result of regular active 
smoking. Four categorizations of tobacco smoke exposure on the basis of saliva 
cotinine concentration were assessed. Thus the study results suggested that, 
additional studies are mandatory to determine the validity of any cotinine 
categorizations and also to check whether using saliva cotinine as a marker of 
tobacco smoke exposure reduces misclassification bias in epidemiologic studies 
must be critically evaluated.42 
Vine FM and his associates in 1993 did a comparative assessment of 
Cotinine concentrations in the semen, urine, and the blood of smokers and non-
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smokers. Of 88 men, 40 were nonsmokers, 23 were light smokers, and 25 were 
heavy smokers were recruited into the study and they collected semen, urine, and 
blood specimens and completed a self-administered questionnaire describing their 
smoking habits and demographic characteristics. 1 ml of blood, urine, and semen 
were collected from each participant and analyzed for cotinine levels via 
radioimmunoassay method. Cotinine analysis showed that, among 48 smokers, 
detectable levels of cotinine were found in 100% of urine and 98% of semen and 
blood specimens. Therefore, the study results reported that blood and semen cotinine 
levels were of similar magnitude but urine cotinine levels were on order of higher 
magnitude.43 
               Jarvis MJ, Feyerabend C, Bryant A, Hedges H and Primatesta P in 2001, 
did a study to correlate plasma cotinine concentrations in non-smoking English 
adults to the smoking behaviour of their partners.  The Health Survey for England 
was designed to generate a representative sample of the population living in private 
households in England. The survey has two stages. At the ﬁrst stage, interviews 
were made in all adults in the households, and the second stage was the nurse visit to 
take biological measures among them. In 1994 to 1996, 77% and 79% of eligible 
households cooperated with the survey interview. Smoking behaviour was being 
gathered at the initial interview, and blood cotinine levels were estimated, a week 
after the interview. Results from this study reported that there was a strong dose 
response relation between cotinine concentrations in non-smoking adults and the 
smoking behaviour of their partners, rising from a geometric mean of 0.31 ng/ml in 
those with non-smoking partners to 1.99 ng/ml in those whose partners smoked 30 
or more cigarettes per day. On average, cotinine concentrations in nonsmokers with 
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a smoking partner were 0.6–0.7% of those in cigarette smokers. And they concluded 
that, if cotinine was taken as a measure of risk relevant dose, the implied increase in 
risk of lung cancer in non-smokers with smoking partners reported have been 
inconsistent with the risk observed in epidemiological studies. Moreover, smoking 
by partners in the home is also a major source of non-smoking adults’ exposure to 
passive smoke being revealed in the study .44 
Piskin S, Sayan C, Durukan N and Senol MS in 2002 evaluated the levels of 
serum iron, ferritin, folic acid and vitamin B12 in patients with RAS and healthy 
controls. The study includes 35 patients with RAS (18 males and 17 females) and 
with no history of aphthous stomatitis were selected as controls (13 males and 13 
females). After a fasting period of 12 hour, blood sample was collected in the 
morning from each patients and serum was separated by centrifuging of 3000RPM. 
The level of Serum iron was established by a colorimetric method, where the levels 
of serum ferritin, folic acid and vitamin B12 were studied by radioimmunoassay 
method. The values of 60 µg/dL (male) and 37 µg/dL (female) were reported as 
normal for serum iron, 18 ng/mL (male) and 9 ng/ mL (female) for ferritin, 3 ng/mL 
and 200pg/ml for folic acid and vitamin B12 respectively. And  they found  that 
Serum iron and  Ferritin  levels were below normal in six RAS patients and 3 
controls whereas  Serum folic acid and vit.B12 levels also reduced  in  RAS patients 
.From this study, in patients with RAS  serum vitamin B12 levels were signiﬁcantly 
decreased. The important contributing factor in the aetiopathogenesis of RAS was 
deficiency of vitamin B12. Further large series of studies clarified the importance 
and the role of other vitamins and minerals in in patients presenting with recurrent 
oral aphthae. 45 
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Atkin PA, Xu X and Thornhill MH in 2002 conducted an epidemiological 
study to compare the blood cotinine levels between a group of patients with minor 
recurrent aphthous stomatitis and a group of  healthy subjects (as controls), 
matched for age and gender. After getting consent, blood samples were collected 
from 84 RAS and 81 controls. A Microplate enzyme immunoassay was used to 
detect the plasma cotinine levels. Result of this study showed that number of RAS 
Patients who were smokers was significantly less than in the control group. 
Moreover, the mean cotinine level among smokers in the RAS group was 
significantly lower than in smokers in the control group. This study also reveals 
that, the group of RAS patients was significantly less likely to contain smokers than 
a matched control population, whereas among smokers the level of cigarette use 
was significantly lower in RAS patients than the control population.8 
Vartiainen E and his associates in 2002 conducted a cross sectional study to 
enlight how valid self-reported smoking is in an area with a community-based 
cardiovascular prophylactic programme and in other certain areas of Finland as well 
as in different demographic groups. A random sample of 2000 people from each of 
the survey areas was taken from the National Population Register. The sample 
incorporates people aged 25-64. The sample was filtered based upon by age groups 
and same genders. Each division contained 250 people. Smoking was evaluated with 
a set of questions. Two types of indices were used to separate the smokers. In the 
ﬁrst group index the following questions were asked: Have you ever smoked in your 
life? (1) no, (2) yes. Those who replied as no were classiﬁed as never smokers. 
Those, who answered yes were asked the following question: When was the last 
time you smoked? (1) Today or yesterday, (2) Between two days and. one month 
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ago,(3)Between one month and half an year ago, (4) From half a year and one year 
ago, (5) More than one year ago. Based on   the above mentioned questionnaire 
results ﬁrst index contained the following four groups: (1) those who had smoked  
currenty as (“current smokers”), (2) those who had smoked two days to one month 
ago, as former smokers (3) those who had smoked longer than one month ago or (4) 
those who had never smoked. For the second index the participants were asked: Do 
you now smoke (1) regularly? (2) occasionally? (3) not at all? . The number of daily 
cigarettes, pipes smoked and cigars consumed were asked from those who reported 
to have smoked within the past month and also the duration, number of cigarettes 
smoked   in a day were calculated.  Then fresh serum samples were collected and 
sent to the laboratory at the National Public Health Institute where they were frozen 
and cotinine level was measured by a Hewlett Packard gas chromatography mass 
spectrometre with a selected ion monitoring mode. And he found that among self-
reported regular smokers, 97.2% of men and 94.9% of women had a cotinine 
concentration of 10 ng/ml or higher in serum. Of those participants who reported to 
have smoked at any time during their life but not during the previous month, 6.3% 
of men and 5.2% of women had a serum cotinine concentration of at least 10 ng/ml. 
The validity of self reporting was similar among subjects from different areas, ages, 
and socioeconomic groups. Therefore, most of the self-reported non-smokers had 
only low or moderate levels of cotinine in their serum and of the general population 
in Finland the validity of self-reported smoking was reported to be high.46 
 Tungtrongchitr R and his associates in 2003 conduced a Cross-sectional 
study of smokers and non-smokers in a military unit at Bangkok, Thailand. To 
investigate the effects of tobacco smoking on serum vitamin B12, folic acid and 
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haematological parameters in healthy Thai smokers and non-smokers. The study 
comprised of 123 male smokers and 66 male non-smokers with age group of 19-60 
years were included in the study. After getting informed consent from each 
participants, 10ml of venous blood sample was collected from each subject after an 
overnight fast. Heparinised blood was used to estimate haematological 
measurements. And they found that, the serum folic acid and hemoglobin 
concentration of smokers was lower than that of non- smokers, whereas16.3% of 
smokers were anaemic when compared with 3.0% of non-smokers. White blood cell 
count was found to be higher in the smokers than in the non-smokers. And they 
reported that, there were low serum folic acid concentrations in the smokers 
comparing with the non-smokers, which might contribute to the development of 
vascular and cardiovascular diseases. 47 
 McRobbie H, Hajek P and Gillison F in 2004 investigated the prevalence, 
severity, and the duration of mouth ulcers in the patients with recently quitted 
smoking habits and checked the effect of different smoking cessation medications 
on the symptom. The sample comprised of 1234 consecutive patients who attended 
The Royal London Hospital Smokers Clinic between March 2000 and December 
2002, achieved at least 1 week of continuous termination of smoking habit, and 
provided the data. Participants assessed their mouth ulcers by rating a mouth ulcer 
item added to the Mood and Physical Symptoms Scale. The subjects made rating 
weekly on three occasions, while still smoking and over 4 weeks following smoking 
cessation. After quitting the habit, 40% of patients developed mouth ulcers, mostly 
in the ﬁrst 2 weeks. The symptom was generally mild, but 8% of them reported as 
having severe ulceration, at the same time ulcers healed within 4 weeks in 60% of 
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the patients affected. The ulcer ratings in patients using oral nicotine replacement 
products were reported to be higher than in those using patch, nasal spray or 
bupropion in the ﬁrst week of abstinence .The study results reported that mouth 
ulcers were more prevalent in the dependent smokers, and also the occurrence of 
ulcers is more associated with other tobacco withdrawal symptoms.  From this study 
they conﬁrmed that mouth ulcers are a common result of   smoking cessation, 
affecting two in ﬁve individuals who quit smoking.11 
Donny CE and his associates in 2008 found out that Data from 
epidemiological studies reported that individual difference in consumption of 
cigarettes per day (CPD) and duration of smoking account for only a small portion 
of the variance in Diagnostic and Statistical Manual of Mental Disorders nicotine 
dependence. This paper elaborates the relationship between cigarettes per day (CPD) 
and years of smoking and the influence of nicotine dependence as measured by the 
Nicotine Dependence Syndrome Scale (NDSS). Furthermore, they evaluated the 
validity of individual differences in nicotine dependence by determining whether 
they are related to cue-evoked craving during the cessation of habit. Datas were 
collected from five laboratorical studies of 489 regular smokers, showed that 
individual differences in both CPD and years smoking had little or no relationship 
with craving. However, the extent of craving was significantly related to the degree 
of nicotine dependence even after controlling for use variables and eliminating the 
craving related items on the NDSS. This study results, reported that among moderate 
to heavy daily smokers, meaningful individual differences in nicotine dependence 
are detected independent of differences in current daily cigarette consumption and 
duration of smoking habits.48 
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Vardavas IC and his associates in 2008 conducted a cross-sectional study 
among 502 farmers from the Valley of Messara in Crete. The subjects were 
randomly selected and investigated the relationship between smoking status, dietary 
intake of vitamin, folate, fiber, fruits, vegetables and serum folate, iron and vitamin 
B12 concentrations. Complete three-day and 24-hr recall questionnaires were 
collected along with anthropometrical, physical activity and clinical datas from all 
participating subjects. After adjusting for age, gender and number of fasting days 
adhered to per year, the study results reported that current smokers have lower 
dietary intake of vitamin C, fiber, fruits and vegetables, while dietary vitamin B1 
intake was found to be higher in smokers in comparison to nonsmokers. Controlling 
age, gender, fasting days and dietary micronutrient intake, serum folate levels were 
found to be decreased among smokers, while serum iron and vitamin B12 levels 
were not affected by smoking status. And they concluded that patients with current 
smoking status affects dietary nutrient intake as well as serum folate levels.49 
Signorelloa LB and his associates in 2009 conducted a study in both sexes to 
assess the cotinine levels among different races and also to provoke the contribution 
of mentholated cigarettes among them.  From Southern Community Cohort Study 
participants, 255 current smokers (63 white men, 65 black men, 65 black women 62 
white women) were evaluated for serum cotinine, level and linear regression was 
used to model the cotinine role on race. After adjusting for the number of cigarettes 
smoked within the last 24 hours with the use of menthol versus non-menthol 
cigarettes. On comparison, white smokers smoked many cigarettes than Black 
smokers, but black smokers had crude mean cotinine levels nearly as high or higher 
than white smokers. Cotinine levels were found to be of 50 ng/ml higher among 
Review of Literature 
 
    Page 23 
 
black than white women and non-signiﬁcantly 12 ng/ml higher among blacks than 
white men, after multivariant analysis reported. Results from the study shown that, 
among menthol cigarette users there was no significant increase in cotinine levels. 
And he concluded  by stating that, the variations in cotinine levels among smokers 
may be due to  racial variations in exposure to smoke and  metabolic changes of 
tobacco smoke constituents in the body, but our ﬁndings do not support a role for 
menthol preference in this disparity.50 
Kozlak TS, Walsh JS and Rajesh V in 2010 conducted a study to compare 
dietary vitamin intake in RAS patients and that of a healthy group. The study 
includes 100subjects, who had suffered at least three episodes of minor RAS in the 
previous 12 months, complete detailed Diet History Questionnaire asked and datas 
were designed and validated by the US National Institutes of Health. DietCalc 
software was used to calculate daily dietary intakes of nine different vitamins in the 
study subjects. Daily dietary intakes were energy-adjusted and   it was compared to 
age- and gender-matched nutrient intake data on 9033 subjects from the US National 
Health and Nutrition Examination Survey. Results of this study subjects showed that 
significantly lower daily intake of vitamin B12 (P< 0.0002) and folate (P< 0.0001) 
in RAS patients as compared to the controls. And he concluded that patients with 
RAS are more likely to have lower dietary intakes of vitamin B12 and folate than 
control group. These results support and extend previous studies by indicating a link 
between the etiology of RAS and hematological deficiencies of vitamin B12 and 
folate. Furthermore, it also suggest us that consuming sufficient amounts of these 
vitamins may be a useful strategy to reduce the number and/or duration of RAS 
episodes.51  
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Milles LJ and his associates in 2011 conducted a cross sectional study in 
elderly individuals with low serum vitamin B-12, those who have high serum folate 
been reported to have greater abnormalities in the following biomarkers for vitamin 
B-12 deﬁciency: low hemoglobin and elevated total homocysteine (tHcy) and 
methylmalonic acid (MMA). This study reveals   that folate exacerbates vitamin B-
12–related metabolic abnormalities. Objective is to determine whether high serum 
folate in individuals with low serum vitamin B-12 increases the deleterious effects 
of low vitamin B-12 on biomarkers of vitamin B-12 cellular function. The study 
sample comprised of 2507 university students provided data on medical history as 
well as exposure to folic acid and vitamin B-12 supplements. Blood was collected to 
measure serum and red blood cell folate (RCF), hemoglobin, plasma tHcy, and 
MMA, holotranscobalamin, and ferritin in serum. Results showed that in subjects 
with low vitamin B-12 concentrations (148 pmol/L), those who had high folate 
concentrations (30 nmol/L; group 1) did not show greater abnormalities in vitamin 
B-12 cellular function in any area than did those with lower folate concentrations 
(30 nmol/L; group 2). And they concluded that in young adult population, high 
folate concentrations did not exacerbate the biochemical abnormalities related to 
vitamin B-12 deﬁciency. These results provided reassurance that folic acid in 
fortiﬁed foods and supplements does not interfere with vitamin B-12 metabolism at 
the cellular level in a healthy population.52 
Ghafoor F and Khan AA in 2012 conducted a case control study at 
Immunoassay lab, NHRC and Department of Dentistry, Shaikh Zayed Hospital, 
Lahore.  Sixty patients of all ages and both genders having history of recurrent 
ulcers over a period of 3-6months were taken as RAS group. Similar number of 
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healthy controls were chosen who did not have any history of aphthous ulcers as 
controls. Proforma was filled for each participant and 5ml of blood sample was 
collected and tested for complete blood picture by Sismex, serum ferritin by ELISA 
method (Biocheck), vitamin B12 and RBC folate by IBL kits from USA. Results 
from this study reported that anemia was present in 24 patients and 18 controls. 
Hematocrit levels were normal in 45 patients and 40 controls. Low levels of RBC 
folate was seen in 26 patients and 26 controls. Vitamin B12 deficiency was present 
in 29(50.1%) patients and none of the controls. The low levels of ferritin was seen in 
6(10.5%) patients and 18(31.5%) controls. This study concludes that Patients with 
RAS had more hematinic deficiencies, particularly of vitamin B12 as compared to 
controls. 53 
Alshaarawy O, Xiao J, Andrew EM, Burchfiel C and Shankar A in 2012 
reported that only few studies have shown that high blood pressure was mainly 
related to never smokers via self-reported secondhand smoke exposure. However, 
there are no studies prior being done by investigating the role of serum cotinine, by 
establishing the relationship between secondhand smoke exposure and high blood 
pressure in never smokers.  The study sample includes only never smokers of (𝑛 = 
2027) from the National Health and Nutrition Examination Survey 2005-2008. This 
study affirms that never smokers exposed to smoking by secondhand smokers had 
prehypertension (𝑛=734), defined as a systolic blood pressure of 120– 139mmHg or 
diastolic blood pressure of 80–89mmHg. There findings shows positive association 
of serum cotinine levels in prehypertension and never smokers. Compared to those 
with cotinine levels in the lowest quartile (≤0.024ng/mL), the multivariable odds 
ratio  of prehypertension among those with cotinine levels in the highest quartile 
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(≥0.224ng/mL) was 1.45(1.00,2.11); 𝑃trend=0.0451. In further subgroup analysis, 
men shows stronger positive association, especially among non Whites, and non 
obese subjects. And he concluded that certain preventative sample of US population 
showed higher amount of second hand exposure which measured higher serum 
cotinine levels were found to be positively associated with prehypertension. 54 
Farasat Khan N,  Saeed M, Chaudhary S and Ghafoor F in 2013 conducted a 
cross sectional study  among  60consecutive subjects, with active RAS were taken as 
the aphthous group and 60 patients with age and gender matched subjects without 
RAS  as the non-aphthous group. 5ml of blood   was taken from both groups to 
analyse the levels of serum B12, and RBC Folate through radio immuno assay and 
serum ferritin with enzyme linked immunosorbent assay method. Complete blood 
count was carried out to determine the level of haemoglobin and haematocrit in both 
groups. Proportion of subjects with lower values was compared and showed a 
significant p-value. Study results suggested that Serum Ferritin (p=0.001), 
haematocrit (p<0.001), RBC Folate (p<0.001) and serum B12 (p<0.001) were 
significantly lower in the RAS group and combined deficiency state (haemoglobin, 
serum Ferritin, haematocrit, RBC Folate and serum B12) was identified in 13% (n= 
8) RAS patients. And they concluded that frequency of haematinic deficiencies was 
higher in RAS patients, in particular Serum B12 and RBC Folate were found to be 
significantly low in aphthous group.55 
Zhu XZ and his associates in 2013 reported that Cotinine, a nicotine 
metabolite, is a biomarker of tobacco. In this study, the Cotinine levels are measured 
based upon the amount of cotinine formation and the rate of cotinine excreted which 
are both mediated by the enzyme CYP2A6.Since CYP2A6 activity vary by genotype 
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and sex hormones, their effect on the levels of cotinine formation and removal from 
bodyfluids were measured in non-smoking Caucasians (Study 1, n=181) infused 
with labeled nicotine and cotinine. The findings were then widely extended to add 
libitum smokers (Study 2, n=163). Results of the Study suggested that 1: Reduced 
CYP2A6 activity altered cotinine formation less than cotinine removal resulting in 
ratios of formation to removal of 1.31 and 1.12 in CYP2A6 reduced and normal 
metabolizers (P=0.01), or 1.39 and 1.12 in males and females (P=0.001), suggesting 
an overestimation of tobacco exposure in slower metabolizers. Study 2: Cotinine 
again magnified tobacco and carcinogen exposure by ≥25% in CYP2A6 reduced 
metabolizers (≈2 fold between some genotypes) and in males. The study concluded 
that, in people with slower, CYP2A6 activity cotinine concentration gets 
accumulated in the body fluids resulting in substantial differences in cotinine levels 
for a given tobacco exposure.56 
Reddy SS and Prashanth R in 2013 done a study among 60 male volunteers 
had the habit history of  using tobacco in either smoke or smokeless form for past 3 
months, 5 times a day were included for the study. The tobacco consumed form 
involves the cigarettes and bidis and chewing tobacco sachets as smokeless form. 
After getting informed consent from each volunteer, 3ml of blood samples were 
collected in the order of 3 session, 1st sample was collected in the early morning, 
following the usage of first tobacco product, the 2nd sample 60 mins later, and the 
3rd sample after 90 mins. Then using Chemiluminescent immunoassay method the 
Serum nicotine levels were analysed. ANOVA and Post Hoc test was used to 
compare and assess the difference in mean serum nicotine levels among all three 
groups. The study findings shown that for cigarette and bidi smokers Serum nicotine 
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levels were significantly high when compared to tobacco chewers. They also added 
the fact that high serum nicotine levels among smokers could be attributed to high 
nicotine content of the tobacco product, method of consumption, rate of nicotine 
absorption and elimination.57 
 Bot M and his associates in 2014 conducted a study among cigarette smokers 
to assess whether cotinine was associated with depression and/or anxiety disorders. 
1,026 smoking adults with or without depressive and/or anxiety disorders were 
included in the Netherlands Study of Depression and Anxiety. They assessed the 
presence of depression and anxiety disorders among the participants by subjecting 
them to the Composite International Diagnostic Interview. Cotinine was measured in 
plasma by solid-phase competitive ELISA method. The result of this study shown 
that patients with depressed or anxious smokers   tend to have more no cigarettes per 
day which ultimately leads to increased level of cotinine in serum. It is also evident 
that after controlling for number of CPD and duration of smoking, depressed and/or 
anxious smokers had lower cotinine levels compared to smokers with no lifetime 
disorder. According to the full regression model, number of CPD was directly 
correlated with serum cotinine levels, whereas current depression and/or anxiety 
disorders in smokers and high body mass index were inversely associated with 
serum cotinine. Finally the study results reported that, after reducing the number of 
CPD, the prevalence of current depression and/or anxiety disorders were associated 
with lower cotinine levels, indicate the different smoking topography or a faster 
cotinine metabolism in individuals with affective disorders. The latter could help to 
explain the higher number of cigarettes smoked and poorer cessation rates among 
depressed or anxious patients.58 
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Chewnoweth JM and his associates in 2014 found out that nicotine 
metabolite ratio (NMR that the ratio of 3′hydroxycotinine to cotinine, or), is strongly 
associated with CYP2A6 genotype, CYP2A6-mediated nicotine and cotinine 
metabolism. Smoking larger no of cigarettes and patients with lower cessation rate 
has higher NMR retrospectively. NMR as a predictive biomarker for recent 
cessation of smokers has being investigated in the study. In this study, CYP2A6- has 
stronger genetic influences on NMR, at the same time demographic and hormonal 
factors alter NMR. Here they analyzed, for the first time together, these sources of 
variation on NMR in smokers screened for this clinical trial (N=1672).Results of the 
study shown that ,Participants  with mentholated cigarette users had lower  NMR of 
16% percent  (P<0.001). When analyzed together in a linear regression model, these 
predictors (each ≤2%) accounted for <8% of total NMR variation among cigarettes 
users.59 
Mohamed S and Janakiram C in 2014 done a case control study to assess the 
association between aphthous ulcer and usage of tobacco. Current evidence shows 
ambiguous relationship between tobacco use and the occurrence of aphthous. He 
studied the relationship between the occurrence of recurrent aphthous ulcers and 
various forms of tobacco usage among  One hundred and two outpatient subjects 
(Males 56.9%) were identified having aphthous ulceration using Natha’s diagnostic 
criteria and were classified as cases, and One hundred and eight subjects (Males, 
70.4%) with no aphthous ulceration were selected randomly as controls. Exposure 
ascertainment of tobacco usage was done by structured interview. The study results 
showed that 0.41 (95% CI 0.19-0.87) for tobacco usage and occurrence of aphthous 
ulceration compared to non-tobacco users. The odds ratio of 0.41 for tobacco usage 
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infers that subjects using tobacco were 59% less likely to have aphthous ulcerations 
compared to nontobacco users. And he concluded   that the study found the 
statistical association between the occurrence of recurrent aphthous ulceration and 
usage of tobacco. The association that exists between smoking and aphthous 
ulcerations of the mouth is in a negative direction. The tobacco users tend to have 45 
% less chance of occurrence of recurrent aphthous ulcer than non-tobacco users.60 
Sumathi K, Shanthi B, Subha Palaneeswari M and Manjula Devi AJ, in 2014 
done an case control study included 50 positive cases of oral ulcers which were 
diagnosed clinically in the ENT Outpatient department OPD of Sree Balaji Medical 
College and Hospital and 25 normal healthy controls. This study was approved by 
the institutional ethical committee. Serum samples were collected from oral ulcer 
patients and from healthy individuals by venipuncture under aseptic precautions, 
after getting written informed consents from each patients. Serum ferritin level was 
estimated by doing a particle enhanced turbidimetric immunoassay method in both 
the oral ulcer patients as well as in healthy individuals. The assay was done by using 
CRM Diagnostics and a Semi-automated analyzer. And they reported that Sixty six 
percent of cases had decreased ferritin values and 34% had normal values, which 
was significant. From this study, it was concluded that one of the causative factors 
for oral ulcers was iron deficiency anaemia and this has to be brought into the 
knowledge of the patients as well as physicians. Therefore, Screening of oral ulcer 
patients by doing serum ferritin estimations is mandatory, so that iron deficiency 
anaemia, which is one of the causes of recurrent oral ulcers cannot be ignored.61 
Rostron BL and his associates in 2015 reported that smokeless tobacco users 
have higher nicotine and toxicant exposure, and studies related to them with have 
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been very limited. Hence they made a trial by analyzing the biomarkers of tobacco 
exposure among 23,684 young adult participants from the National Health and 
Nutrition Examination Survey from 1999 to 2012. Serum cotinine,urinary4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), blood lead, blood cadmium, 
blood mercury, urinary arsenic, and urinary N-acetyl-S-(2-cya- noethyl)-L-cysteine  
are the  following biomarkers analyzed . Then they calculated geometric mean 
concentrations and ratios for each biomarker .The study findings suggested that 
specifically smokeless tobacco users had higher geometric mean concentrations of 
serum cotinine and NNAL than cigarette smokers. Smokeless tobacco users also had 
increased concentrations of blood lead compared with nontobacco users. Based on 
limited sample sizes, NNAL concentrations for smokeless tobacco users appear to 
have reduced from 2007 to 2008 (geometric mean ¼ 1013.7 pg/mg creatinine, 95% 
CI, 738.9-1390.8)to2011to2012(geometricmean¼325.7pg/mg creatinine, 95% CI, 
159.6-664.9). Thus the study results highlighted that Exclusive smokeless tobacco 
users have increased range of exposure to nicotine and carcinogenic tobacco speciﬁc 
nitrosamines, as measured by cotinine and NNAL biomarker concentrations, than 
cigarette smokers. 62 
Marsot A and Simon N in 2016 found out that E-cigarettes are marketed as 
nicotine delivery devices. Commonly reported reasons for usage of E-cigarettes 
include to quit smoking, to reduce urge to smoke, or the perceived lower risk 
alternative to smoking. In order to know the actual amounts of nicotine delivered 
from E- Cigarettes this study was undertaken to review all the published studies 
concerning nicotine or cotinine levels following e-cigarette use. The study search 
was conducted from the PubMed database, from 1985 to January 2014, using the 
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following terms: electronic cigarette(s), e-cigarette(s), electronic nicotine delivery 
system, cotinine, and nicotine. Articles were excluded if they not fufilled our study 
criteria. References of all pertaining articles were also taken into consideration. 
Results from this study suggested that eight studies were selected and following 
information were gathered from the articles: population size, age of participants, 
recruitment, inclusion and exclusion criteria, concentration of nicotine in refills 
liquids, study sample design, and observed concentrations. Following the design of 
studies, plasma nicotine Cmax was observed between 0 and 5 ng/mL (no significant 
changes) or between 13.9 and 16.3 ng/mL (similar to a tobacco cigarette) with a 
Tmax between 70 and 75 minutes. And he concluded that the peak concentration of 
nicotine appears to be dependent on the use and dose level of e-cigarette cartridge. 
The value of this peak concentration is similar to the value found with a tobacco 
cigarette. From this study they added the fact that, future research is also required to 
found out the parametric manipulation of devices characteristics (brand, content 
liquid, and nicotine concentration) and user behavior (ie, puff topography) that 
might contribute to safety and efficacy. Other studies are also necessary to confirm 
these results.63 
Kim S in 2016 suggested that cotinine is commonly used as a biomarker to 
validate self-reported smoking status, and also for the detection of optimal cotinine 
cutoff value for distinguishing true smokers from true nonsmokers. This review 
elaborates how the cutoff values have been derived, and the issues involved in the 
generalization of a cutoff value. In this study, we conducted an English-language 
literature search in PubMed using the keywords “cotinine” and “cutoff” or “self-
reported” and “smoking status” and “validation” for the years 1985–2014. We 
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obtained 104 articles, 32 of which provided (1) sensitivity and speciﬁcity of a cutoff 
value and (2) determination methods for the given cutoff value. We found that the 
saliva cotinine cutoff value range of 10–25 ng/mL, serum and urine cotinine cut off 
of 10–20 ng/mL and 50–200 ng/mL, respectively, have been commonly used to 
validate self-reported smoking status using a 2×2 table or a receiver operating 
characteristics (ROC) curve. We also found that recent large population-based 
studies in the U.S. and UK reported lower cutoff values for cotinine in serum (3 
ng/mL) and saliva (12 ng/mL), compared to the traditionally accepted ones (15 and 
14 ng/mg, respectively).64 
Sari K, Yildirim T and Sari N in 2016 done a prospective, cross-sectional 
study enrolling 195 patients with RAS (RAS group) and 217 healthy controls 
(control group). After getting informed consent from each subject and also the 
approval from the local ethical committee , Blood samples were drawn from the 
RAS group and control group for measuring blood Hb and vit B12 concentrations. 
The blood Hb and vit B12 levels were investigated by an auto analyzer. And they 
found out that RAS group had significantly lower mean Hb levels than the control 
group (P<0.001).No significant variations in the mean vit.B12 level was reported 
between the study group and controls. Around58(29.7%) patients were diagnosed as 
Hb deficient in the RAS group and 21(9.7%) patients in controls.VitB.12 deficiency 
was diagnosed in 63(32.3%)individuals in the RAS group and 32(14.7%)individuals 
among controls. Thus study results concluded that, vit.B12 and Hb deficiencies were 
found to be higher in patients with RAS when compared to the control group.28 
Ko K and his associates  in 2016 conducted the study to address the absence 
of Korean studies to found out the accuracy of immunoassays and liquid 
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chromatography–tandem mass spectrometry (LC-MS/MS) for the observation of 
serum cotinine and also to assure the optimal serum cotinine cut-off level for 
recognizing current smokers from nonsmokers. Serum specimens were collected 
from 120 subjects and they were randomly chosen to represent a broad distribution 
of urine cotinine levels based on a retrospective review of questionnaire. Then he 
determined serum cotinine levels using the IMMULITE 2000 XPi Immunoassay 
System and LC-MS/MS.  Then correlation was made between IMMULITE serum 
cotinine, urine cotinine, and LC-MS/MS serum cotinine levels using ROC curve to 
identify the most appropriate IMMULITE serum cotinine cut-off level for 
differentiating current smokers from nonsmokers. The study findings showed that 
IMMULITE serum cotinine levels correlated with both urine cotinine and LC-MS/ 
MS serum cotinine levels, with range of 0.958 and 0.986, respectively. The most 
appropriate serum cotinine cut-off level for recognizing current smokers from 
nonsmokers was found to be 13.2 ng/mL using IMMULITE. And they finalised that 
this was the foremost study to explore the use of LC-MS/MS for the measurement of 
serum cotinine and also to determine the optimal serum cotinine cut-off level for the 
IMMULITE immunoassay. Further the results of this study also mentioned certain 
guidelines for differentiating current smokers from nonsmokers in the Korean 
population.65 
Wu YC, Wu YH, Wang PY, Chang YJ, Chen MH and Sun A in 2016 found 
out that some of the Recurrent Aphthous Stomatitis (RAS) patients had concomitant 
atrophic glossitis (AG). So he done a study  by assessing whether RAS patients with 
AG (AGþ/RAS patients) or without AG (AG/RAS patients) had anemia and 
hematinic deﬁciencies and also to evaluate whether RAS combined with AG or RAS 
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itself was a signiﬁcant factor causing anemia and hematinic deﬁciencies in 
AGþ/RAS or AG/RAS patients, respectively. The mean corpuscular volume and 
mean blood hemoglobin (Hb), iron, vitamin B12, and folic acid levels were assessed 
and compared between any two of three groups of 160 AGþ/RAS patients, 195 AG-
/RAS patients, and 355 healthy control subjects. And he found that both AGþ/RAS 
and AG/RAS patients had signiﬁcantly lower mean Hb, iron, and vitamin B12 levels 
as well as signiﬁcantly higher frequencies of Hb, iron, vitamin B12, and folic acid 
deﬁciencies than healthy control subjects. Moreover, AGþ/RAS patients had 
signiﬁcantly lower mean Hb and serum iron level (for women only) and signiﬁcantly 
higher frequencies of Hb and iron deﬁciencies than AG/RAS patients. And he 
concluded that some of the AGþ/RAS or AG/RAS patients have anemia and 
hematinic deﬁciencies and specifically AGþ/RAS patients have severe anemic 
statuses and iron deﬁciency than AG/RAS patients.66 
Singh D in 2016 done a study by investigating the effect of smoking on serum 
Homocysteine and vitamin B12 concentration evaluated at Arth Diagnostics Private 
Limited, Udaipur. Serum Homocysteine and vitamin B12 levels were measured in 300 
male subjects. Out of which 150 were smokers and 150 non-smokers with an age 
range of 50 to 60 years. Only chronic smokers who were smoking for more than 20 
years were included in the study. 150 male chronic cigarette smokers who were 
smoking for more than 20 years, with an age range of 50 to 60 years, were included 
for this study after obtaining written informed consent.  Blood samples was collected 
after 12 hours of an overnight fast into plain tubes. And serum was obtained by 
centrifugation and samples were analysed for each parameter. The concentration of 
Homocysteine in smokers was 17.51 ± 7.44 µmol/L and in non-smokers was 8.61 ± 
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5.32 µmol/L. Instead the concentration of vitamin B12 in smokers was 346.83 ± 
125.76 pg/ml and in non-smokers was 481.43 ± 174.65 pg/ml. There was significant 
increase in concentration of Homocysteine in serum of chronic smokers as compared 
to non-smokers while it was inverse in case of vitamin B12. Thus this study concludes 
that smoking increases Homocysteine levels and decreases vitamin B12 levels leading 
to increase cardiovascular disease risk among smokers.67 
Tidgundi MS, Moinuddin K and Baig MSA in 2017 done a case control 
study by comparing Ferritin and Vitamin B12 levels in Recurrent Aphthous 
Stomatitis patients. The study group comprised of 64 cases with RAS and 60 
controls, which was conducted in a tertiary care hospital in South India from May 
2015 to May 2016. The study was approved by the institutional ethics committee, 
and after getting informed consent from all the patients 3ml of blood sample was 
withdrawn and centrifuged at 3000 rpm for 10 minutes, for the analysis of serum 
Ferritin by Enzyme Linked Immunosorbent Assay and serum B12 by radio 
immunoassay method. And they reported that statistically significant differences 
were observed in the serum levels of ferritin and vitamin B12 between the two 
groups ie. 64% of the patients had low serum ferritin levels and 54% of the patients 
had low serum vitamin B12 levels. From this study, it was known that Screening of 
aphthous ulcer patients by measuring serum ferritin and vitamin B12 levels was 
mandatory and it is also essential for recurrent aphthous ulcer patients to have 
nutritional diet containing iron and vitamin B12.68 
Duque A and his associates in 2017 conducted a multicenter study among 
578 patients, to assess the association between smoking and its relation to 
periodontal diseases based upon the level of blood biomarkers. It has been reported 
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that self-reports from smokers should be accompanied by cotinine test. Progression 
of periodontal disease was evaluated clinically, depending upon the clinical 
attachment loss and Smoking behavior was enquired by questionnaire interview. 
After getting consent from the patients, blood sample was drawn and serum cotinine 
levels were analysed. Many study reports suggested that serum cotinine level of 10 
ng/ml was the most accurate cut-off point for smokers.  However, this study findings 
concluded that self-reported smoking and serum cotinine test ≥ 10ng/ml are more 
accurate, systematic method to assess the patient’s smoking status and it could be 
remarkably used in samples with large population and multicenter studies for 
evaluating serum samples.69 
Shivasekar M, Vinothini VM and Rupesh Kumar Y in 2018 conducted a 
cross sectional study between smokers and nonsmokers. The study comprised of 200 
subjects out of which 100 were   smokers and rest were nonsmokers. The smokers 
group included, the subjects who were smoking filtered cigarette, a minimum of 5 
(maximum 10) per day with duration of ≤10 years. After getting written informed 
consent, from all subjects with 12 hr fasting, 3 ml of blood samples was collected 
and centrifuged at 3000 RPM for 10 mins. Then, Serum ferritin level was measured 
using immunofluorometric method and for iron, total iron-binding capacity (TIBC) 
was measured using standard kits in Beckmann coulter auto-analyzer AU 400, on 
the same day of sample collection. And they found out that, the subjects with 
smoking habits   showed a significant rise in serum ferritin level. From the study 
results they concluded that, serum ferritin serves as the most reliable indicator of 
iron status and also added the fact that cigarette smoking has adverse effect on 
serum ferritin as well as other hematological parameters.70 
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Bao ZX, Shi J, Yang XW and Liu LX in 2018 conducted comparative 
assessment of Hematinic investigations, including serum ferritin, folic acid, and 
vitamin B12 deficiencies among 517 RAS patients and 187 healthy controls along 
with gender and age factors. Results of this study shown that, frequency of incidence 
and hematinic deficiencies were found to be higher among RAS patients when 
compared to controls. When gender and age were taken into consideration, notable 
variations in hematinic deficiencies were observed among young female patients. 
Serum ferritin deficiency was more common among young and middle-aged female 
RAS patients whereas Both Serum folate and serum vitamin B12 deficiencies were 
much more common in the young adult group of male RAS patients. Logistic 
regression analysis reported that both gender and age factors have significant 
association with the presence of hematinic deficiencies in the RAS patients. And 
they concluded that remarkable variations in hematinic deficiencies were detected 
among different genders and age groups among RAS patients.71 
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MATERIALS AND METHOD 
 
SOURCE OF DATA 
This study was carried out in the Department of Oral Medicine and 
Radiology, Sree Mookambika Institute of Dental Sciences, Kulasekharam, and 
Department of Biochemistry, Sree Mookambika Institute of Medical Sciences, 
Kulasekharam, Kanyakumari district, Tamil Nadu. Clinical trial registration was 
made with Clinical Trial Registry of India (CTRI) (REF/2017/11/015768). 
METHOD OF SELECTION OF DATA 
1. SAMPLE SIZE 
Total number of subjects - 40 
 Group I -   Healthy Volunteers   (10)           
 Group II -  Recurrent Aphthous Stomatitis with no smoking habit (10) 
 Group III -  Smokers without Recurrent Aphthous Stomatitis (10) 
 Group IV -   Smokers with Recurrent Aphthous Stomatitis (10)       
2. SELECTION OF CASES 
Inclusion and Exclusion Criteria: 
Group I:  Healthy Volunteers 
INCLUSION EXCLUSION 
 Healthy volunteers aged between 
18- 50 years 
 Patients with no history of RAS 
lesions. 
 Patients who are willing for blood 
donation. 
 History of any systemic disease in 
which oral aphthous ulceration may be 
a feature. 
 Concurrent medication with systemic 
Steroids, immunomodulatory or 
Cytotoxics drugs.  
 Patients  with  pregnancy  
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Group II:  Recurrent Aphthous Stomatitis with no smoking habit 
INCLUSION EXCLUSION 
 History of regularly recurrent 
episodes of Minor oral aphthous 
ulceration over the preceeding 6 
months or longer. 
 An average of at least two ulcers 
per month over the previous 6 
months. 
 
 Patients with history of Smoking and 
any other Tobacco Habits.  . 
 Concurrent medication with systemic 
Steroids, immunomodulatory or 
Cytotoxics drugs.  
 History  of any systemic disease in 
which oral aphthous  ulceration may 
be a feature 
Group III:  Smokers without Recurrent Aphthous Stomatitis 
INCLUSION EXCLUSION 
  Patients with a history of smoking 
>100 cigarettes and who are 
current smokers. 
 Patients who are using Nicotine in 
any other forms. 
 Patients with no history of RAS   . 
 History  of any systemic disease in 
which oral aphthous  ulceration may 
be a feature 
 Concurrent medication with systemic 
Steroids, immunomodulatory or 
Cytotoxics drugs.  
Group IV:   Smokers with Recurrent Aphthous Stomatitis 
INCLUSION EXCLUSION 
 History of regularly recurrent 
episodes of minor oral aphthous 
ulceration over the preceeding 6 
months or longer. 
 Patients with a history of 
smoking >100 cigarettes and who 
are current smokers.  
 Patients with no history of smoking 
habits. 
 Patients with history of any systemic 
diseases. 
 Concurrent medication with systemic 
Steroids, immunomodulatory or 
Cytotoxics drugs. 
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PARAMETERS TO BE STUDIED 
 Plasma Cotinine 
 Serum Ferritin  
 Serum   vitamin B12 
MATERIALS REQUIRED 
 Kidney tray 
 Mouth Mirror 
 Explorer 
 Mask 
 Gloves 
  Disposable Syringe (5ml) 
 Needle ( 24 Gauge ) 
 Gauze 
 Test tube 
KIT - PLASMA COTININE MICROPLATE ENZYME LINKED IMMUNO 
ASSAY KIT.  
Indented Use:  To assay the level of Human Cotinine in human  plasma.   
Materials Provided:   
(1). Microtiter Coated Plate (96 wells) – 1 no (2). Human Cotinine Biotin Conjugated 
Detection Antibody, 1 ml – 1 vial 3. Standard, 32ng/L - 0.5 ml (4). Streptavidin: HRP 
Conjugate - 6ml (5). Wash Buffer (30X) - 20ml (6). Standard Diluent - 3ml                            
(7). Substrate A - 6ml (8). Substrate B - 6 ml (9). Stop Solution - 6 ml (All reagents 
should be stored at 2 ºC to 8 ºC). 
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Reagent Preparation:    
a. Bring all reagents to Room Temperature before half an hour.  
b. To make 1X Wash Solution, add 10 ml of 30X Wash Buffer in 290 ml of DI water.   
Specimen Collection:   
a. Specimens should be clear and non-hemolyzed. Samples should be run at a 
number of dilutions to ensure correct specific quantitation.  
b. Serum - Coagulate at room temperature for 10-20 mins and centrifuge for 20-min at 
2000-3000 rpm. Then, remove the supernatant. If precipitation appears, recentrifuge.  
B. SERUM FERRITIN KIT. 
Use: The Ferritin Reagent is for the estimation of ferritin concentrations in human 
serum on the Beckman Coulter AU clinical chemistry analyzers.  
Sample Collection and Reagent 
- Serum(1ml)  
Reagents: 
- Ferritin Reagent 
Final concentration of reactive ingredients  
- Glycine buffer (R1: pH 8.3, R2: pH 7.3) 170 mmol/L  
- Latex particles coated with rabbit anti-human ferritin  
- Preservative  
Preparation of reagents  
- R1 is ready for use and can be placed directly on board the instrument. 
The R2 latex solution should be cross bred by inversion 5 – 10 times 
prior to placing on the instrument and at weekly intervals thereafter.  
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Storage of Reagent  
The reagents are stable, kept unopened, up to the mentioned expiry date 
when stored at 2–8°C. Once open, reagents stored on board the instrument are stable 
for 60 days approximately.  
 
C. SERUM VITAMIN B12 KIT.  
Intended Use: For the estimation of vitamin B12 concentration in human serum. 
MATERIALS PROVIDED 
Access Vitamin B12 Reagent Pack Cat. No. 33000: 100 determinations, 2 
packs, 50 tests/pack  
 Store upright and refrigerate at 2 to 10°C. Refrigerate at 2 to 10°C for a 
minimum of two hours before use on the instrument. Stable until the expiration 
date stated on the label when stored at 2 to 10°C.  Stable at 2 to 10°C for 14 days 
after initial use. Signs of possible deterioration are a broken elastomeric layer on 
the pack or control values out of range.  If the reagent pack is damaged (i.e., 
broken elastomer), discard the pack. All antisera are polyclonal unless otherwise 
indicated. 
 R1a: Paramagnetic particles coated with goat anti-mouse IgG: mouse 
monoclonal anti-intrinsic factor complexes, TRIS buffered saline, surfactant, 
bovine serum albumin (BSA), < 0.1% sodium azide, and 0.1% ProClin** 300. 
 R1b: Borate buffer with surfactant, cobinamide, and < 0.1% sodium azide.  
 R1c: Porcine intrinsic factor-alkaline phosphatase (bovine) conjugate in TRIS 
buffered saline, surfactant, human serum albumin (HSA), < 0.1% sodium azide, 
and 0.25% ProClin 300.  
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 R1d: 0.5N sodium hydroxide solution (NaOH) with 0.005% potassium cyanide 
(KCN), CORROSIVE. R1e: 0.02% acetic acid solution with dithiothreitol 
(DTT). 
SPECIMEN COLLECTION AND PREPARATION 
1. Serum(1ml) is the recommended samples.  
2. Observe the following recommendations for handling, processing, and storing 
blood samples  
 Collect all blood samples observing routine precautions for venipuncture.  
 Allow serum samples to clot completely before centrifugation. • Keep tubes 
stoppered at all times.  
 Within two hours after centrifugation, transfer at least 500 µL of cell-free 
sample to a storage tube. Tightly stopper the tube immediately.  
 Store samples tightly stoppered at room temperature (15 to 30°C) for no 
longer than eight hours.  
 If the assay will not be completed within eight hours, refrigerate the samples 
at 2 to 8°C.  
 If the assay will not be completed within 24 hours, or for shipment of 
samples, freeze at -20°C or colder.  
 Thaw samples only once. 
 3. Use the following guidelines when preparing specimens:  
 Ensure residual fibrin and cellular matter has been removed prior to analysis.  
 Follow blood collection tube manufacturer’s recommendations for 
centrifugation.  
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4. Each laboratory should determine the acceptability of its own blood collection 
tubes and serum separation products. Variations in these products may exist between 
manufacturers and, at times, from lot-to-lot.  
5. Avoid assaying hemolyzed samples. 
 
PROCEDURE IN DETAIL   
 This study will be carried out in the Department of Oral Medicine and 
Radiology, SMIDS and Department of Biochemistry, SMIMS, Kulasekharam. 
Individuals satisfying the inclusion and exclusion criteria will be included in the 
study. A total of 3ml blood sample was obtained after informed consent from every 
willing participant. The sample was centrifuged for 20minutes at 2000- 3000rpm. 
Plasma and Serum were separated.1ml of Plasma was used for cotinine estimation, 
while the remaining 2ml for serum Ferritin and serum vitamin B12 estimation.  
The study comprises of two stages: 
Stage 1: 
 A comprehensive history including the personal, family and past medical 
history will be recorded in a case history proforma.  A detailed intraoral examination 
is performed in all participants. Once a lesion is detected patients are referred to the 
Department of Biochemistry for further evaluation. 
 
HUMAN COTININE ELIZA 
PRINCIPLE 
 The kit uses a double-antibody sandwich enzyme-linked immunosorbent 
assay (ELISA) to assess the level of Human Cotinine in samples Cotinine is added 
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to wells pre-coated with monoclonal Cotinine antibody. After incubation, added 
Cotinine secondary antibodies labelled with biotin followed by Streptavidin-HRP to 
form immune complex. Unbound immune complex is removed by washing step. 
Then addition of Chromogenic Solution A and B, develops blue colour, and stop 
solution is added to stop the reaction. The concentration of Human Cotinine is 
directly proportional to the colour developed. 
ASSAY PROCEDURE:   
1) Bring all reagents to room temperature before use. It is strongly 
recommended that all Standards and Samples should be run in duplicates or 
triplicates. A standard curve is required for each assay.  
2) Prepare the Standards Dilution.  
3) Remove the number of strips required for the assay.   
4) Pipette out 50 µl of Standards and 40 µl Samples into the respective wells as 
mentioned in the work list. Note do not add the sample, Biotin Conjugate 
and Streptavidin-HRP to the blank well.  
5) Pipette out 10 µl of Biotin Conjugate into each sample well. Do not pipette 
into the blank and standards wells.   
6) Pipette out 50 µl of Streptavidin-HRP Conjugate into each sample and 
standards well. Do not pipette into the Blank well.  
7) Cover the plate and incubate for 1 hour at 37 °C in the incubator.  
8) Aspirate and wash plate 4 times with 1X Wash Buffer and blot residual 
buffer by firmly tapping plate upside down on absorbent paper. Wipe off any 
liquid from the bottom outside of the microtiter wells as any residue can 
interfere in the reading step. All the washes should be performed similarly. 
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Then add Substrate A 50 μl, then Substrate B 50 μl to each well including 
Blank well. Gently mixed, incubate for 10 min at 37 ℃ in dark.  
9) Pipette out 50 µl of Stop Solution. Wells should turn from blue to yellow in 
colour.  
10) Read the absorbance at 450 nm within 15 minutes after adding the Stop 
Solution blanking on the zero standards.   
 
Stage 2: 
 In the lab 1ml of blood sample will be collected from the patients. Then, the 
Plasma Cotinine assay was performed using a commercial 96 well microplate 
Cotinine – Specific Competitive immunoassay. Ten microlitre of the test samples, 
control samples or calibration standards were added to the wells of a 96 well coated 
with immobilized Cotinine specific monoclonal antibody. This was immediately 
followed by 100microlitre of enzyme conjugate containing horseradish peroxidase 
labelled cotinine. These were inoculated in the dark for 30min at 21oC.The reaction 
was then stopped by the addition of 100 microlitre 2.0 N Sulphuric acid. The 
cotinine concentration in each well was then quantified by measuring the light 
absorbance at wavelengths of 450 and 630nm and comparing with the standard 
curve. This assay has a relative sensitivity of 100% and relative specificity of 90.8% 
and intra assay variability of < 7.5%. Each sample was assayed in duplicate and the 
mean of the two values used for analysis. 
ASSESSMENT OF SERUM FERRITIN AND VITAMIN B12: 
 2ml of blood sample is taken and analyzed for Serum Ferritin and vitamin 
B12 level using Chemiluminescent assay method. 
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Chemiluminescent Assay Method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESTIMATION OF SERUM FERRITIN: 
    Serum ferritin is an indicator of body iron stores: it has been shown to 
correlate with stainable bone marrow iron. Measurements of ferritin aid in the 
diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron 
overload) and iron deficiency anemia. 
PROCEDURE: 
Latex agglutination reactions occur as a result of antibody-coated latex beads 
aggregating if antigen is present in sufficient quantity. Immune complexes formed in 
solution scatter light in proportion to their size, shape and concentration. Under 
conditions of antibody excess, increasing amounts of antigen result in higher scatter. 
Turbidimeters measure the reduction of incident light due to reflection, absorption, 
or scatter. In the Beckman Coulter procedure, the measurement of the decrease in 
light intensity transmitted (increase in absorbance) through particles suspended in 
standards, controls, samples 
 
Add conjugateAdd 
Incubate shaking at RT for 2 hours 
Wash 
Add substrate 
Read plate 
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solution as a result of complexes formed during the antigen-antibody reaction, is the 
basis of this assay. The anti-ferritin reagent composed of, a suspension of 
polystyrene latex particles, coated with polyclonal rabbit anti-ferritin antibodies of 
uniform size. When serum, containing ferritin, is admixed with the anti-ferritin 
reagent, an agglutination mixture occurs. This is measured spectrophotometrically 
on Beckman Coulter Chemistry Analyzers.  
ESTIMATION OF SERUM VITAMIN B12 
The Access Vitamin B12 assay is a paramagnetic particle, chemiluminescent 
immunoassay for the quantitative determination of vitamin B12 levels in human 
serum and plasma (heparin) using the Access Immunoassay Systems.Vitamin B12 is 
the name given to any one of a group of substances termed cobalamins. 
They are composed of a tetrapyrole ring surrounding a central cobalt atom 
and differ with respect to the side groups attached to the cobalt atom. The 
predominant form in serum is methylcobalamin while the predominant cellular form 
is 5’ deoxyadenosylcobalamin.1 Cyanocobalamin (MW 1355) is the most stable and 
is used as a reference compound for measuring serum cobalamin concentrations. 
PRINCIPLES AND PROCEDURE 
The Access Vitamin B12 assay is a competitive binding immunoenzymatic 
assay. A sample is added to a reaction vessel along with alkaline potassium cyanide 
and dithiothreitol. This treatment denatures B12 binding proteins and converts all 
forms of vitamin B12 to the cyanocobalamin form. After neutralization, intrinsic 
factor-alkaline phosphatase conjugate and paramagnetic particles coated with goat 
anti-mouse IgG: mouse monoclonal anti-intrinsic factor are added to the sample. 
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Vitamin B12 in the sample binds to the intrinsic factor conjugate, preventing the 
conjugate from binding to the solid phase anti-intrinsic factor. After incubating in a 
reaction vessel, unbound materials are washed away while the, materials which 
bound to the solid phase are held in a magnetic field. Then, the chemiluminescent 
substrate Lumi-Phos* 530 was added to the vessel and light produced by the 
reaction is measured with a luminometer. Thus the amount of photon produced is 
inversely proportional to the concentration of vitamin B12 in the sample. The 
amount of analyte in the sample is determined by means of a stored, multi-point 
calibration curve. 
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CP 3 - Human Plasma Cotinine ELISA Kit 
 
 
 
 
CP - 4 Serum Ferritin Kit 
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CP 6- Recurrent Aphthous Stomatitis 
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CP 7 - Smoker with RAS 
 
 
 
CP 8 -Smoker without RAS 
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CP 9 - Blood Sample Collection 
 
 
 
(a)                                              (b) 
 
  
(c) 
CP 10 (a, b, c) - Estimation of Plasma Cotinine and ELISA Reader 
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CP-11(a, b, c) Estimation of Serum Vit B12 and Ferritin in 
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CP- 12 Estimation of Serum Vit. B12 and Ferritin by CLIA Method 
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RESULTS AND OBSERVATION 
The present study was undertaken to compare the Plasma Cotinine Serum 
Ferritin and Serum Vitamin B12 among smokers and nonsmokers with Recurrent 
Aphthous stomatitis patients versus Controls. 
      The study comprises 40 patients with four groups (Group I - Healthy 
Volunteers, Group II - Recurrent Aphthous Stomatitis with no smoking habit, 
Group III - Smokers without Recurrent Aphthous Stomatitis and Group IV - 
Recurrent Aphthous Stomatitis in smokers).  Table-1 depicts the Mean Serum 
Vitamin B12, Serum Ferritin and Plasma Cotinine values of 4 Groups. 
The analysis demonstrated that on comparing the mean Serum Vit.B12 and 
Ferritin among 4 groups, the patients with RAS had significantly low levels of 
Serum Vit. B12 and Ferritin whereas these parameters are raised in Smokers and 
also showed significant difference among Smokers with RAS(Graph - I). On 
Comparing the Plasma levels of Cotinine among 4 groups showed that significant 
rise in levels of Plasma cotinine among smokers( Group-III) and  decreased levels of 
Plasma Cotinine among Smokers with RAS and RAS patients( Graph -2). 
Table-2 depicts the Mean Serum Vitamin B12, Serum Ferritin and Plasma 
Cotinine values of Healthy patients with other Groups. On Comparing the 
prevalence of Serum Vit.B12 and Ferritin levels among Healthy Volunteers and 
Smokers without Recurrent Aphthous Stomatitis reveals that Serum vit.B12 and 
Ferritin levels were decreased in Healthy Volunteers (Graph -3). The Plasma 
Cotinine levels was found to be decreased in healthy patients when compared to 
Smokers without Recurrent Aphthous Stomatitis. (Graph -4). 
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On Comparing the mean Serum Vit.B12 and Ferritin levels among patients 
with Recurrent Aphthous Stomatitis and Smokers with RAS showed that decrease in 
the levels of these parameters in patients with Recurrent Aphthous Stomatitis 
(Graph-5). The Plasma Cotinine levels was found to be significantly raised in 
Recurrent Aphthous Stomatitis patients (Graph-6). 
Table-6 depicts the Multiple Comparison of mean Serum Vitamin B12, 
Serum Ferritin and Plasma Cotinine values between each groups with the 
othergroup. And showed that P value less than 0.05 significant when compared each 
group with other groups. 
Hence, the present study results reveals that prevalence of RAS is more 
common among patients with Serum Ferritin and Vitamin B12 deficiency at the 
same time Plasma Cotinine levels also plays an essential role in Recurrent Aphthous 
Stomatitis patients especially among smokers and it can be also considered as one of 
the major etiological factor because its levels were highly reduced among smokers 
with RAS when comparing to other groups. 
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Table-1: Mean serum vitamin B12, ferritin and plasma cotinine values of 
different groups  
Groups 
Vitamin B12  
(pg/ml) 
(MEAN±SD) 
Ferritin (ng/ml) 
(MEAN±SD) 
Plasma cotinine 
(ng/ml) 
(MEAN±SD) 
Group-I 345.80±1.94 44.21±2.70 0.0099±0.10 
Group-II 330.20±1.18 27.95±2.76 0.0034±0.01 
Group-III 427.30±1.94 158.14±9.79 0.0100±0.01 
Group-IV 382.50±1.91 118.29±7.50 0.0013±0.01 
 
Table-2: Comparison mean vitamin B12, ferritin and plasma cotinine values of 
Group-I with other groups  
Groups 
Vitamin B12  
(pg/ml) 
(MEAN±SD) 
p 
value 
Ferritin 
(ng/ml) 
(MEAN±SD) 
p 
value 
Plasma 
cotinine 
(ng/ml) 
(MEAN±SD) 
p 
value 
Group-
I 
345.80±1.94  44.21±2.70  0.0099±0.10  
Group-
II 
330.20±1.18* 0.04 27.95±2.76* 0.001 0.0034±0.01* 0.01 
Group-
III 
427.30±1.94* 0.001 158.14±9.79* 0.001 0.0100±0.01* 0.01 
Group-
IV 
382.50±1.91* 0.001 118.29±7.50* 0.001 0.0013±0.01* 0.01 
(*p<0.05 significant compared Group-I with other groups) 
 
Results and Observation 
 
   Page 54 
 
Table-3: Comparison mean vitamin B12, ferritin and plasma cotinine values of 
Group-II with other groups  
Groups 
Vitamin B12  
(pg/ml) 
(MEAN±SD) 
p 
value 
Ferritin 
(ng/ml) 
(MEAN±SD) 
p 
value 
Plasma 
cotinine 
(ng/ml) 
(MEAN±SD) 
p 
value 
Group-I 345.80±1.94* 0.04 44.21±2.70* 0.001 0.0099±0.10* 0.01 
Group-II 330.20±1.18  27.95±2.76  0.0034±0.01  
GroupIII 427.30±1.94* 0.001 158.14±9.79* 0.001 0.0100±0.01* 0.01 
Group-
IV 
382.50±1.91* 0.001 118.29±7.50* 0.001 0.0013±0.01* 0.01 
(*p<0.05 significant compared Group-II with other groups) 
 
Table-4: Comparison mean vitamin B12, ferritin and plasma cotinine values of 
Group-III with other groups  
Groups 
Vitamin B12  
(pg/ml) 
(MEAN±SD) 
p 
value 
Ferritin 
(ng/ml) 
(MEAN±SD) 
p 
value 
Plasma 
cotinine 
(ng/ml) 
(MEAN±SD) 
p 
value 
Group-
I 
345.80±1.94* 0.001 44.21±2.70* 0.001 0.0099±0.10* 0.01 
Group-
II 
330.20±1.18* 0.001 27.95±2.76* 0.001 0.0034±0.01* 0.01 
Group-
III 
427.30±1.94  158.14±9.79  0.0100±0.01  
Group-
IV 
382.50±1.91* 0.001 118.29±7.50* 0.001 0.0013±0.01* 0.01 
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Table-5: Comparison mean vitamin B12, ferritin and plasma cotinine values of 
Group-IV with other groups  
Groups 
Vitamin B12  
(pg/ml) 
(MEAN±SD) 
p 
value 
Ferritin 
(ng/ml) 
(MEAN±SD) 
p 
value 
Plasma 
cotinine 
(ng/ml) 
(MEAN±SD) 
p value 
Group - 
I 
345.80±1.94* 0.001 44.21±2.70* 0.001 0.0099±0.10* 0.01 
Group-
II 
330.20±1.18* 0.001 27.95±2.76* 0.001 0.0034±0.01* 0.01 
Group-
III 
427.30±1.94* 0.001 158.14±9.79* 0.001 0.0100±0.01* 0.01 
Group-
IV 
382.50±1.91  118.29±7.50  0.0013±0.01  
 
Table-6: Multiple comparison mean vitamin B12, ferritin and plasma cotinine 
values between the groups  
Groups 
Vitamin B12  (pg/ml) 
(MEAN±SD) 
Ferritin (ng/ml) 
(MEAN±SD) 
Plasma cotinine 
(ng/ml) (MEAN±SD) 
Group-I 345.80±1.94 44.21±2.70 0.0099±0.10 
Group-II 330.20±1.18* 27.95±2.76* 0.0034±0.01* 
Group-III 427.30±1.94*,# 158.14±9.79*,# 0.0100±0.01*,# 
Group-IV 382.50±1.91*,#,$ 118.29±7.50*,#,$ 0.0013±0.01*,#,$ 
(*p<0.05 significant compared Group-I with other groups, #p<0.05 significant 
compared Group-II with other groups, $p<0.05 significant compared Group-III 
with other groups) 
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Graph 1: Mean serum vitamin B12, ferritin values of different groups 
 
 
Graph 2: Mean plasma cotinine values of different groups 
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Graph -3: Comparison mean vitamin B12, ferritin of Group-I with Group-III 
 
 
Graph-4: Comparison mean plasma cotinine values of Group-I with Group-III 
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Graph-5: Comparison mean vitamin B12, ferritin of Group-II with Group-IV 
 
 
Graph-6: Comparison mean plasma cotinine values of Group-II with Group-IV 
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DISCUSSION 
The present study was undertaken to compare the Plasma Cotinine, Serum 
Ferritin and Vitamin B12 among smokers and nonsmokers with Recurrent Aphthous 
stomatitis patients versus Controls. The study was conducted in the Department of 
Oral Medicine and Radiology and Department of Biochemistry, Sree Mookambika 
Institute of Dental Sciences, Kulasekharam. The study comprises 40 patients with 
four groups. They are Group I - Healthy Volunteers (10), Group II - Recurrent 
Aphthous Stomatitis with no smoking habit(10), Group III - Smokers without 
Recurrent Aphthous Stomatitis (10) and Group IV - Recurrent Aphthous Stomatitis 
in smokers(10). Samples were selected based on our preformatted inclusion and 
exclusion criteria. 
Recurrent aphthous stomatitis (RAS) is a chronic inflammatory relapsing, 
remitting oral mucosal disease, which continue for a variable period of time and 
affects virtually 50% of the world population, with three classic forms namely 
minor, major and Herpetiform types. These subtypes vary with respect to 
morphologic, distribution, severity and prognosis.2,3 
Inspite of numerous studies, the exact etiology of RAS has not been 
described, but the abnormality in Host factors such as Genetic, Immunological, 
Haematological, Vitamin deficiency, Physical or Emotional stress and 
environmental factors such as microtrauma, chemical injury and infections have 
been implicated. Hematinic deficiency (Serum Ferritin and Vitamin B12) in 
particular was found to be twice as common.4 The precise mechanism of how 
hematinic deficiencies causing RAS are still unclear, however  it outbreaks from 
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oral epithelial atrophy, injury to mucous membrane barrier and negative influence 
on the epithelial integrity were reported as the primary mechanisms behind it. 
Instead of malabsorption, Insufficient dietary intake, may be the main reason for 
hematinic deficiencies has been reported.51 
Discomfort in patients with recurrent aphthous stomatitis is relatively high 
ie.. it increases the flow of saliva and interfere with day to day activities like eating, 
drinking, speaking and can have significant effect on patients quality of life. Since 
the etiology of RAU is unclear, the treatment is aimed mainly to relieve pain. The 
patients’ life quality has been highly  affected by pain from  these mucosal 
lesions.45Although  the mechanism of  RAS  is  not fully understood,  Many 
investigators observed lower prevalence rate of RAS in smokers when compared to 
nonsmokers, increase in  the  incidence of RAS  following the termination of 
smoking  ,  and resolution of  lesions upon restarting of  cigarettes smoking. It is 
mainly due to the presence of nicotine content in smokers which has protective 
effect on oral mucosa by causing keratinization5,6,8,12. 
 Cotinine is the major decadence product of nicotine metabolism and it can be 
assayed in various biological Fluids (Including Plasma, Serum, Saliva, Urine, and 
Semen). Due to its relatively longer half-life in circulation, Cotinine is used as a 
most common biomarker used to assess nicotine exposure and abstinence. In the 
present study, cotinine level has been estimated in plasma, because plasma cotinine 
concentration is highly correlated with tobacco smoke exposure from both direct 
smoke inhalation via cigarette consumption and environment exposure via 
secondhand smoke.15-20 
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Oral Epithelial cells have high turnover rate and Vit.B12and Folic acid play 
important role in DNA synthesis and cell division. Vitamin B12 deficiency 
suppresses the cell mediated immunity, which affects the synthesis of DNA in the 
epithelial cells and leads to pathological changes in the epithelium of tongue and the 
buccal mucosa. Its deficiency also impairs the metabolism of folate which can lead 
to folic acid deficiency, Folic acid helps in the regeneration and healing process of 
oral epithelium. Deficiency of Folate also causes development of megaloblastic 
anaemia.72 
Iron is present in the structure of Hb and is essential for epithelial function. 
Ferritin is a globular protein which exist intracellularly, in which iron is aggregated 
in a soluble, nontoxic form. Ferritin can store upto 4500 Fe(III) atoms. Iron 
homeostasis and its storage is maintained by Ferritin. Regulation of ferritin synthesis 
was achieved by intracellular iron at both transcripsional and transational levels. 
Low iron levels lead to decreased ferritin synthesis. Basically Ferritin in serum well 
correlates with iron stores in the body. RAS is known to be caused by iron 
deficiency which leads to epithelial atrophy.73 
Cotinine have protective effect on oral mucosa by causing increased 
keratinization and this keratin layer act as a mechanical and chemical barrier against 
trauma or microbes. And it also hypothesized that nicotine may be responsible agent 
for reduction in  RAS prevalence rate in smokers because it modulate local immune 
responses, as it has been shown to induce Tcells anergy and inhibit the production of 
pro- inflammatory cytokines such as interleukins(2,6,8,10 )and tumour necrosis 
factor alpha and also activates the release of adrenocorticotrophic hormone and 
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cortisol,   through the hypothalamus –pituitary –adrenal axis and leading to further 
suppression of inflammatory pathways.5,6,8 
Number of studies have been reported that, pure nicotine is a safe 
component, although it depends on the dose. Until date, tobacco has had only a 
prophylactic role against aphthous ulcers, therefore the role of submerged nicotine in 
tobacco as a therapeutic factor should be taken in to account.24Hence, these 
interesting factors leads us to undertake this study to found out the comparison of 
this Plasma Cotinine, Serum Ferritin and Vit.B12 levels among smokers and 
nonsmokers with Recurrent Aphhous Stomatitis versus controls. 
                      In the present study we found out that patients with smokers contain 
significantly high Plasma Cotinine, it was mainly due to the increased levels of 
cigarettes smoking, on basis of number of package and duration, when compared 
with smokers with RAS. And this study results were consistent with the 
epidemiological study done by Atkin et al in 2002 to compare the blood cotinine 
levels beween a group of patients with minor recurrent aphthous stomatitis and a 
group representative of the general population, matched for age and gender. Result 
of his study showed that number of RAS patients who were smokers was 
significantly less than in the control group. Furthemorethe mean cotinine level 
among smokers in the RAS group was significantly lower than in smokers in the 
control group.8 
                      And also our present study showed decreased prevalence rate of   Recurrent 
Aphthous Stomatitis among smokers (tobacco users) when compared to 
nonsmokers, due to protective effect of nicotine by causing keratinizaion of oral 
Discussion 
 
   Page 63 
 
mucosa among smokers. This results was found to be consistent with the case 
control study done by Mohamed S and Janakiram C in 2014,   One hundred and 
two outpatient subjects (Males 56.9%) having aphthous ulceration and one hundred 
and eight subjects (Males, 70.4%) with no aphthous ulceration were selected 
randomly as controls to assess the association between aphthous ulcer and usage of 
tobacco in various forms. And he concluded   that the tobacco users tend to have 45 
% less chance of occurrence of recurrent aphthous ulcer than non-tobacco users.60 
Many studies has been reported that cut off values for distinguishing smoker 
from nonsmoker was found to be 20 ng/ml, however studies done by Benowitz et al 
in 2009 suggested that serum cut off values for distinguishing smoker from 
nonsmoker was found to be much smaller value ie. 3.08 to2.99 ng/ml for adults and 
adolescents this study results was consistent with the present study results of Plasma 
cotinine levels of smokers when compared to nonsmokers and healthy volunteers.74 
              In the present study, on comparing the Serum Vit.B12 and Ferritin levels 
among 4 groups. The patients with RAS had significantly low levels of Serum Vit 
B12 and Ferritin whereas these parameters are raised in Smokers and also showed 
significant difference among Smokers with RAS. RAS patients of our study showed 
decreased dietary intake of Vit.B12 and iron. This study results were consistent with 
study done by Sumathi K et al in 2014 among, 50 positive cases of oral ulcers and 
25 normal healthy controls. And she reported that Sixty six percent of cases had 
decreased ferritin values and 34% had normal values, which was significant. From 
this study, it was concluded that Screening of RAS patients by doing serum ferritin 
estimations is mandatory.61 
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           On Comparing the Serum Ferritin level among smokers and nonsmokers in 
this present study, Serum Ferritin levels were found to be increased in smokers, this 
study results is also found to be similar to the cross sectional study done by 
Shivasekar et al in 2018 between smokers and nonsmokers comprised of 200 
subjects out of which 100 were   smokers and rest were nonsmokers. And he found 
that, the subjects with smoking habits   showed a significant increase in serum 
ferritin level. Increase in serum Ferritin in smokers were mainly due to high 
oxidative stress, which were produced by numerous oxidants and pro-oxidants 
contained in the cigarette smoke. In order to regulate iron catalyst oxidative stress, 
lung epithelial cells can rapidly increase the expression of ferritin protein.70 
            In this present study patients with RAS had showed significantly low levels 
of Vit.B12 when compare to healthy volunteers and Smokers, which was found to 
be correlate with the studies done by Ghafoor F and Khan AA in 2012 among Sixty 
patients of all ages and both genders having history of recurrent ulcers over the past 
period of 3-6months.Similarnumberofhealthycontrolswerechosen who did not have 
any history of aphthous ulcers. Results of this study suggestedthat Vit. B12 
deficiency was present in 29(50.1%) patients and none of the controls. The low 
levels of ferritin was seen in 6(10.5%) patients and 18(31.5%) controls. And he 
concluded that patients with recurrent aphthous ulcers had more hematinic 
deficiencies, particularly of vitamin B12 as comparedto controls.54 
         In our present study Vit.B12 was found to be increased among smokers when 
compared to nonsmokers was also similar to the study results done by 
Tungtrongchitr R and his associates in 2003 among smokers and non-smokers to 
investigate the effects of tobacco smoking on serum vitamin B12, folic acid and 
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haematological parameters .One hundred and twenty-three male smokers and sixty-
six male non-smokers from the same unit were selected as controls. The ages of the 
subjects were in the range of 19-60 years. And he found that serum vit.B12 levels 
increased in smokers when compared to nonsmokers because smokers are highly 
prone to take foods rich in vit.B12 .47 
In the present study, we found that patients with RAS among genders, 
females had shown more serum ferritin deficiencies when compared to males. Many 
studies reported that because of more prevalence rate of Iron deficiency among 
females when compared to males, this study results was also consistent with study 
done by Bao ZX and his associates in 2018, Hematinic deficiencies in patients with 
RAS among genders and age.71 
In the present study we found decreased levels of Serum Vit.B12 among 
RAS patients when comparing to healthy patients and smokers without RAS. It has 
been also reported that serum B12 is the most common frequently found haematinic 
deficiency and its deficiency suppresses the cell mediated immunity and causes 
changes in the epithelium of buccal mucosa and tongue, which was found to be 
similar to the study results done by Piskin et al in 2002 among 35 RAS patients and 
healthy controls.45 
Khan NF et al in 2013 found out that haematinic deficiency was high among 
RAS patients especially serum B12 and folate levels were significantly low among 
RAS patients. From this study we also found that patients with RAS had 
significantly low levels of serum B12when compared to healthy volunteers. Studies 
have suggested that owing to lower dietary intake of vit.B12 and Folate.55 
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In the present study we found that optimal cut off values for distinguishing 
smoker from non-smoker was serum 10ng/ml, cotinine content in serum depends 
mainly upon the duration of smoking before the time of questionnaire about the 
smoking habits, which was also consistent, with the study done by Duques et al in 
2017 among smokers and periodontitis patients.69 
Jarvis et al in 2002 done an study, Passive smokers in home among 
nonsmokers with smoking partners he found out that average cotinine concentration 
in nonsmokers with a smoking partner were 0.3ng/ml-1.99% of those in cigarette 
smokers, which was also similar to the study results found among nonsmokers to the 
smoking partners of our study. And also study shown the smoking by partner in the 
home is a major source of nonsmoking adults exposure to passive smoking.44 
From this study, on comparing the plasma cotinine levels among RAS 
patients and Smokers with RAS, it was found that Plasma Cotinine levels were 
significantly reduced among smokers with RAS .It was well evident that Cotinine 
plays an one of the etiological factor for RAS and also Cotinine substitutes can be 
supplemented for this patients for prevention of further recurrence. 
Hence the present study sheds light on the importance of investigating Serum 
Ferritin and Vit.B12 in patients with RAS and also shows the need for close 
supervision regarding the   dietary intake of Iron and nutritional supplements, 
especially Vitamin B12 in such patients. The study also reveals the fact that the 
prevalence of RAS is high among patients with recent cessation of smoking habits, 
therefore Nicotine Replacement Therapy can be suggested for these patients. 
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CONCLUSION 
Recurrent Aphthous Stomatitis (RAS) is one of the most common oral 
mucosal lesions that physicians and dentists encounter. RAS is characterized by 
recurring ulcers confined to the oral epithelium in patients with no other signs of 
systemic disease. RAS occurs in 20% of the population and if the ethnic or 
socioeconomic group is specifically investigated the incidence is 5 to 50%. Despite 
their distinct characteristics, all forms of RAS have a significant impact on quality of 
life and interfere with activities of daily living. 
Cotinine is the major decadence product of nicotine metabolism and it can be 
assayed in various biological Fluids. Due to its relatively longer half life in 
circulation, Cotinine is used as a most common biomarker used to assess nicotine 
exposure and abstinence. At the same time, Cotinine testing provides a more 
accurate measure than exhaled air Carbon monoxide, one of the most widely used 
biomarkers in smoking research and has proved to be more desirable in examining 
nicotine intake due to its ability to estimate tobacco smoke exposure over a longer 
time frame than CO monitoring. 
The present study was undertaken to compare the Plasma Cotinine, Serum 
Ferritin and Vitamin B12 among smokers and nonsmokers with Recurrent Aphthous 
stomatitis patients versus Controls. Significant observation of Plasma Cotinine 
levels were seen among Smokers and Smokers with RAS. And patients with RAS 
contain decreased levels of Serum B12 and Ferritin when compared to others. 
Knowledge from the study suggested that, pure nicotine(not the other 
components of tobacco) is a safe component, although it depends on the dose. Until 
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date, tobacco has had only a prophylactic role against aphthous ulcers, therefore the 
role of submerged nicotine in tobacco as a beneficial factor should be taken in to 
account. Among smokers and nonsmokers the prevalence of RAS is high among 
patients with recent discontinuation of smoking habits, therefore Nicotine 
Replacement Therapy can be suggested for this patients. It is also vital to analyse the 
Serum Ferritin and Vit.B12 levels as a prior investigative procedure as well as close 
supervision regarding the dietary intake of Iron and nutritional supplements 
especially Vitamin B12 while managing patients with Recurrent Aphthous 
Stomatitis.  
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ANNEXURE 
 
  
 
  
 
CONSENT FORM 
INFORMATION FOR PARTICIPANTS OF THE STUDY 
Dear Volunteers, 
We welcome you and thank you for your keen interest in participation 
in this research project. Before you participate in this study, it is important for you 
to understand why this research is being carried out. This form will provide you all 
the relevant details of this research. It will explain the nature, the purpose, the 
benefits, the risks, the discomforts, the precautions and the information about how 
this project will be carried out. It is important that you read and understand the 
contents of the form carefully. This form may contain certain scientific terms and 
hence, if you have any doubts or if you want more information, you are free to ask 
the study personnel or the contact person mentioned below before you give your 
consent and also at any time during the entire course of the project. 
1. Name of the Principal Investigator: S.V. Dhanya 
   Second Year Post Graduate student  
   Department of Oral Medicine  
   and Radiology 
   Sree Mookambika Institute of Dental  
   Sciences, Kulasekharam 
2. Name of the Guide:                   Dr Shashi Kiran M, MDS 
  Reader 
                                                     Department of Oral Medicine and 
  Radiology 
     Sree Mookambika Institute of  
     Dental Sciences, Kulasekharam,  
  KanyaKumari District-629161  
3. Name of the Co-Guide:   Dr. Tatu Joy. E  MDS 
  Professor and Head 
                                                               Department of Oral Medicine and  
  Radiology. 
                                                   Sree Mookambika Institute of  
  Dental Sciences. 
  KanyaKumari District-629161  
4. Institute:  Sree Mookambika Institute of  
  Dental Sciences, 
 Kulasekharam, Tamilnadu 
 
5. Title of the study:  
 “Comparison of Plasma Cotinine, Serum B12 and Serum Ferritin Levels between 
smokers and non-smokers with Recurrent Aphthous Stomatitis Versus Controls - A 
Cross sectional study”.  
 
6. Back ground information: 
Recurrent Aphthous Stomatitis is the most common inflammatory ulcerative 
condition of the oral cavity affecting 20% of the population with three classic forms 
minor, major and herpetiform. Despite numerous studies, the etiology of RAS has 
not been determined, but the abnormalities in Host factors such as Genetic, 
Immunological, Hematological, Vitamin deficiency, Physical or emotional stress 
and environmental factors such as microtrauma, chemical injury, infections and 
smoking have been implicated. However, hematinic deficiency (Serum ferritin and 
serum vitamin B12) were twice as common in patients with RAS. 
Cotinine is a nicotine metabolite with a long half life in the circulation, and 
measurement of levels can give a reliable indication of whether the patient is a 
smoker. Cotinine Levels in plasma increase with an increase in cigarette smoke 
exposure. The blood Plasma Cotinine level that is accepted as defining a smoker is a 
level > 25 ng ml-1. Levels above 25 ng ml-1 correlate well with the number of 
cigarettes smoked per day. Cotinine Levels between 0 and 25 ng ml-1 occur in 
individuals exposed to cigarette smoke passively. 
 
7. Aims and Objectives: 
 To assess whether the blood Cotinine levels have a positive influence in 
Recurrent Aphthous Stomatitis.   
 To assess the role of serum ferritin and serum vitamin B12 in Recurrent   
Aphthous Stomatitis Versus Controls. 
 
8. Scientific justification of the study: 
There are two probable theories regarding the preventive effect of smoking 
on RAS: 
 Cigarette smoking prevents aphthous ulcer by causing an increase in 
localized keratinization of the oral mucosa. 
 Nicotine activate the release of adrenocorticotrophic hormone and cortisol 
leading to further suppression of inflammatory Pathways. 
 
9. Procedure for the study: 
 Obtain clinical records regarding data such as history of Recurrent aphthous 
Ulcer, smoking habits. 
 An informed consent will be obtained from all participants. 
 A band will be wrapped around the arm, 3-4 inches above the collection site 
(superficial vein that lies within the elbow pit) 
 The site will be cleaned with 70% alcohol in an outward spiral, away from 
the zone of needle insertion 
 The needle cap will be removed and held in line with the vein, pulling the 
skin tight with a small and quick thrust, the vein will be penetrated using the 
needle 
 The required amount of blood sample (3ml) will be collected by pulling the 
plunger of the syringe out slowly 
 The wrap band will be removed, gauze will be placed on the collection site, 
and the needle is removed 
 The blood will be immediately transferred into the blood container, which 
has the appropriate preservative/clot activator/anti-coagulant. 
 Then the blood sample will be analysed for plasma Cotinine, serum ferritin and 
serum B12. 
10. Expected risks for the participants: 
NIL 
11. Expected benefits of research for the participants:  
 You will get a better knowledge about your oral health condition and various 
treatment and preventive options available to improve your oral health. 
12. Maintenance of confidentiality: 
a. You have the right to confidentiality regarding the privacy of your medical 
information (Personal details, results of physical examinations, 
investigations, and your medical history). 
b. By signing this document, you will be allowing the research team 
investigators, other study Personnel, sponsors, institutional ethics committee 
and any person or agency required by law to view your data, if required.  
c. The results of study performed as part of this research may be included in 
your medical record.  
d. The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
13. Why have I been chosen to be in this study? 
a. Chosen because of grouping under the inclusion and exclusion criteria  
b. Need of good sampling size 
14. How many people will be in the study? 40 
15. Agreement of compensation to the participants (In case of a study related 
injury): 
 No related injury anticipated. Patient will be taken care in case of 
complication and medical treatment will be provided. 
16. Anticipated prorated payment, if any, to the participant(s) of the study:   
 Not applicable. 
17. Can I withdraw from the study at any time during the study period? 
 The participation in this research is purely voluntary and you have the right 
to withdraw from this study at any time during the course of the study 
without giving any reasons.  
 However, it is advisable that you talk to the research team prior to stopping 
information. 
18. If there is any new findings/information, would I be informed? Yes 
19. Expected duration of the participant’s participation in the study:   1day 
20. Any other pertinent information:   
No other information 
21. Whom do I contact for further information? 
 
 
 
 
 
 
 
 
 
Place:  
Date:      Signature of Principal Investigator 
     
 
                                                                         Signature of the participant 
 
 
 
 
 
For any study related queries, you are free to contact: 
Dr. S.V. Dhanya 
Post Graduate Student, 
Department of Oral Medicine and Radiology 
Sree Mookambika Institute of Dental Sciences 
Kulasekharam, 
Kanyakumari District-629161 
8531066480 
drdhanyasv2009@gmail.com 
 
Jl×Rp YôdÏ êXm 
ØRp TôLm 
BWônf£«p TeÏùTßúYôÚdLô] RLYp Ï±l× 
 
AuTôokR TeúLtTô[oLú[, CkR BWônf£«p ReLû[ DÓTÓj§ùLôs[ 
ªÏkR BoYjÕPu ØÝU]ÕPu LXkÕùLôs[ YkR YúWúYtTô[oLû[ 
YWúYt¡ú\u. ¿eLs CkR BWônf£«p TeùLÓjÕdùLôsYRtÏ Øu CkR 
BWônf£ GRtLôL SPjRlTÓ¡\Õ GuTûR ùR°YôL ×¬kÕùLôs[úYiÓm. 
EeLÞdÏ úRûYVô] Aû]jÕ ®TWeLÞm ¸úZ ùLôÓdLlThÓs[Õ. CkR 
BWônf£«u êXm HtTÓm SuûULs, HúRàm BTjÕLs Utßm ARtLôL 
Utßm GqYôß CkR BWônf£ úUtùLôs[lTÓm Øû\Lû[Ùm 
ùR¬®dLlThÓs[Õ. C§p ùLôÓdLlThÓs[ ®TWeLû[ ùR°YôL T¥jÕ ×¬kÕ 
ùLôs[úYiÓm. ¿eLs BWônf£«p TeúLtTô[oL[ôL Jl×Rp YZeÏYRtÏ 
Øu× EeLÞdÏ HtTÓm A±®Vp NôokR NkúRLeLs Utßm BWônf£ 
NmTkRlThP NkúRLeLs Aû]jÕm CkR BWônf£«u GkR LôXLhPj§Ûm 
¿eLs T¥Yj§p Ï±l©hP ST¬Pm úLhÓ  ùR°ÜTÓj§d ùLôs[Xôm. 
 
PôdPo.Gv.®.RuVô
M.D.S
M.D.S
மெடிக்கல்
 
  
  
 
 
k½X ]{Xw þ `mKw  
]T\hpambnklIcn¡p¶ hyànIfpsSAdnhntebv¡v 
 
{]nbs¸« k¶² tkhItc, 
 R§Ä \n§sfkzmKXwsN¿p¶p.AtXmsSm¸wCu ]T\hpambnklIcn¡m\pÅ k¶²XtbmSv \µn 
tcJs¸Sp¯p¶p.  \n§ÄCu ]T\ n¯Â ]s¦Sp¡p¶Xn\p ap³]v Cu ]T\w  F´n\mWv 
\S¯s¸Sp¶XvF¶vAdntb-Xp-v. AXn\mÂ Cu t^md¯nÂKthjW 
]T\ n¯sâhnhc§fpwaäpwhniZambntcJs¸Sp n¯bncn¡p¶p.  Cu ]T\ n¯sâcoXn, Dt±iw, {]tbmP\w, 
A]ISkm²yX, t¢iw, ap³IcpXÂ, F§s\ Cu ]T\w  ap³t]m«psIm-pt]mIp¶pF¶n§s\  
FÃmhnhc§fpwt^md¯nÂtcJs¸Sp n¯bncn¡p¶p.  kZbw Cu  hnhc§Ähmbn¨p a\Ênem¡phm³  
A`yÀ°n¡p¶p.  Cu hnhc§fnÂimkv{X]camb ]Z§Ä DÅXn\mÂkwib\nhmcW¯n\p {][m\ 
]T\IÀ¯mhnt\mtSmXmsgtcJs¸Sp¯nbncn¡p¶ hyànItfmtSmt^mdwH¸nSp¶Xn\p ap³t]m AsÃ¦nÂ Cu 
]T\ n¯sâImemh[n Xocp¶Xphtctbmkao]n¡mhp¶XmWv.  
1. apJy KthjI³ :  tUm.Fkv.hn. [\y 
    t]mÌp{KmPpthäv hn²ymÀ°n\n(Fw.Un.Fkv) 
    Un¸mÀ«vsaâvHm v^HmdÂ  saUnkn³&tdUntbmfPn,   
    {ioaqImw_nI C³Ìnäyq«v Hm v^sUâÂ  kb³kv, 
    IpetiJcw þ 629 161.  
     
2. {][m\ amÀ¤ZÀin : tUm. iinInc¬ Fw, Fw. Un. Fkv. 
doUÀ 
Un¸mÀ«vsaâvHm v^HmdÂ  saUnkn³&tdUntbmfPn 
{ioaqImw_nI C³Ìnäyq«v Hm v^sUâÂ  kb³kkv, 
IpetiJcw. 
     
 
3. klamÀ¤ ZÀin : tUm. ämäptPmbv. C. Fw. Un.Fkv. 
s{]m^kÀ&slUv 
Un¸mÀ«vsaâvHm v^HmdÂ  saUnkn³&tdUntbmfPn 
{ioaqImw_nI C³Ìnäyq«v Hm v^sUâÂ  kb³kkv, 
IpetiJcw. 
 
4. C³Ìnäyq«v  : {io. aqImw_nI C³Ìnäyq«v Hm v^sUâvÂ  kb³kkv 
    ]S\new, IpetiJcw, I\ymIpamcn þ 629 161. 
    Xangv\mSv. 
 
5. ]T\ hnjbw:  
¹mkvam tIm«n³, kodwB12aäpw. kodw s]cnSn³Afhv, ]pIhen¡p¶hcptSbpw, 
]pIhen¡m¯hcptSbpwXmcXaywAXns\ d¡dâvB v^X kvtÌmssassS¸oSv F¶pw hmbvtcmKt¯mSvtNÀ¶p 
ÅXmcXay ]T\w. 
 
 
6.  e£y§fpwDt±i§fpw 
 »UvtIm«n\n\v Afhv RAS þÂ \Ã  kzm[o\w sNep¯p¶pt-msb¶pÅhnebncp¯Â 
 dn¡dâvB v^XÊvsÌmassä{dnkvI¬t{SmÄknepwskdwsjdnänâpskdw sshäan³ _n.12 hnsâbpw  
{]m[m\ywhnebncp¯pI.  
 
7.   Cu KthjW¯nsâ {]kn 
ssa\À, taPÀ, slÀ]änt^mhnkvF¶n§s\ {][m\ambvXcwXncn n¨cn¡p¶ BhÀ¯n¨phcp¶ 
B v^XkvsÌmassäänkv km[mcWbmbn  20% BfpIfpsShmbnepwI-phcp¶p.  ]T\§fneqsSbYmÀ° 
ImcWwIs-¯m\mbn«nÃF¦nepw  ]mc¼cym càkw_Ôamb {]iv\§Ä, hnäman\pIfpsSIpdhv, imcocnIhpw 
am\knIhpamb ]ncnapdp¡wkqjvamWp¡Ä, BLmXw, cmkhkvXp¡Ä ]pIhenF¶nhCXn\v ImcWambn 
]dbs¸Sp¶p.  cà n¯se s^dnänsâbpw hnäman³ B12sâbpw IpdhvC¯cw tcmK§fnÂ 
Cc«nbmbnI-phcp¶p. tIm«n\n³ F¶ \nt¡m«n³ saät_msfävcàNw {IW¯nÂ IqSpXÂ 
lm v^sse v^DÅXn\mÂ ChbpsS AfhvAf¡p¶Xp hgn ]pIhen¡mc³ As¶¶p ÅhnizmkIcambkqN\ 
e`yamIp¶XmWv. knKdänsâ ]pIizkn¡p¶XvIqSp¶X\pkcn v¨ ¹mkvabnse  tIm«n\nsâsheepwIqSp¶XmWv. 
»Uv ¹mkva tIm«n\n³ Afhv 25 Fw.PnFw.FÂF¶XnepwIqSpXÂ  DÅ hyànsb  ]pIhen¡mc³  
F¶vhntijn n¸¡mhp¶XmWv.  25 F³.Pn.FÂ F¶ AfhvIqSnb ¹mkvabnse tIm«nsâsehepw , 
]pIhen¡m³ HcpZnhkw  hen¨  knKdänsâF®hpw X½nÂ t\À_ÔamWpÅXv. tIm«n\n³ sehÂ 0þ25 , 
F³.Pn.Fw.FÂ  F¶pÅXv ]mÊohvkvamtIÀkns\ kqNn n¸¡p¶p 
 
8.  ]T\s¯¡pdn¨pÅimkv{X \ymboIcWw 
dn¡dâv B v^XÊvsÌmasäänknÂ ]pIhenbmÂ D-mImhp¶ {]Xntcm[s¯ kaÀ°n¡m³  c-p 
kn²mÔ§fmWpÅXv.  
 HmdÂayqtImkbnse {]mtZinIrXsIcmänss\tkjsâAfhvIqSp¶Xphgn ]pIhen¡p¶XpaqewB^XÊv 
BÄk³ XSbp¶XmWv.  
 A{Sns\mtImÀ«nsImt{«m n^¡vtlmÀtamWnsâbpw  It{-mfnsâbpw]pd´ÅÄ  \ntIm«n³ Dt¯Pn n¸¡p¶ 
hgntImiPze\w IqSpXembn ASn¨aÀ¯s¸Sp¶p.  
 
9.]T\ coXn 
 sd¡dâv B v^XkvAÄkdpw ]pI henioe§fpw hnhcn¡p¶ ]qÀÆImetcJIÄ AS§nb ¢o\n¡Â 
dt¡mÀUpIÄ tiJcn¡pI.  
 ]s¦Sp¯ FÃmhcnÂ \n¶pwAndthmsSbpÅ k½XwtiJcn¡pI. 
 càtiJcWØm\¯p \n¶pw  3þ4 C©n\v apIfnembnssI¿ÂHcp _m³Uv sI«pI. 
 càtiJcWØm\ v¯ \n¶phr¯ n¯ÂAIte¡v 70% BÂItlmÄ D]tbmKn v¨hr n¯bm¡pI. 
 Xz¡vicn¡pwhen v¨ ]nSn¨Xn\ptijw  \oUnÂIym v¸Ducnamänshbn\n\v t\À¡mbnshbv¡pI.  
 shbn\ntebv¡vkqNnsNdpXpw s]«¶pÅXpambDu¶enÂIbäpI. 
 knd©nsâ  ¹_À ]Xnsb ]pdIntebv¡vhen¨psIm-vBhiyambcà n¯sâkmw]nÄtiJcn¡pI.  
 {hm v¸ _mâvAgn¨pamänbXn\p tijwcàtiJcWØmt¯bv¡v ]ªnsIm-v ]nSn¨psIm-v \oUnÂamäpI.  
 3ml tiJcn¨ càw A\ptbmPyamb {]nkÀthäohv t¢m«vBÎnthäÀ/ BâvsImbmKpeâv AS§nb 
s»UvIt-bv\dntebv¡v XÂ£Ww amäpI.  
 càkmw]nÄ D]tbmKn v¨ ¹mkva tIm«vskdw, s^dnän³, skdw sshäan³ B12th-nhniIe\w sN¿pI.   
 
10. ]T\w aqew ]s¦Sp¡p¶ BÄ¡v D-mIm³ CSbpÅ A]IS km[yX þ A]IS km²yX 
CÃ. 
 
11. tcmKnIÄ¡v {]Xo£n¡p¶ KpW§Ä 
 tcmKnBhiys¸SpIbmsW¦nÂ Cu ]T\¯ns\mSphnÂGähpw \Ã NnInÕmcoXn 
\nÀt±in¡p¶XmWv. 
 
12.  hnhc§Äclkyambnkq£n¡ptam ? AsX 
 
13.  Fs¶ F´psIm-vCu ]T\¯nÂDÄs¸Sp¯n ? 
\n§ÄR§fpsS ]T\¯n\v A\ptbmPybmb LSI§Ä ]men¡s¸Sp¶ 
amXrIm]cambDZmlcWamIp¶p. Cu ]T\w aqewtcmK\nÀ®b¯n\v klmbhpwkaql¯n\v 
\·bpw {][m\w sN¿p¶p.  
14.  F{X BfpIÄ Cu ]T\¯nÂDÄs¸Sp¶p.    40 
 
15.  ]T\w aqeap-mIp¶ £X§Ä¡v \ã]cnlmc¯n\pÅ k½Xw ?   
]T\IÀ¯mhvNnInÕmsNehvhln¡p¶XmWv. 
 
16.  GsX¦nepwhn[¯nÂthX\w e`n¡ptam þ CÃ 
 
17.  Ft¸mÄthWsa¦nepw  F\n¡v  Cu ]T\¯nÂ \n¶v  ]n·mdmtam þ
 kz´wXmÂ]cy{]Imcw Cu ]T\¯nÂ \n¶vFt¸mÄthWsa¦nepw 
]n·mdmhp¶XmWvImcW§Â \ÂImsXXs¶. F¶ncp¶mepwKthjWkwLt¯mSv 
]n·mdp¶Xn\pap³]v kwkmcn¡phm³ R§Ä \n§tfmSvA`yÀ°n¡p¶p.  
 
18.  Cu KthjW¯nsâ ^eambn ]pXnb Fs´¦nepw Is-¯epIfps-¦nÂ 
AXvFs¶ Andbn¡ptam ?  AsX 
 
19.  Cu ]T\¯nsâkabssZÀLyw F{XbmWv?   HcphÀjw 
 
20.  CXnsâ `mKambnFs´¦nepwIqSpXÂhnhc§Äth- 
 
21.  IqSpXÂhnhc§Ä¡mbnXmsg ]dbp¶hsc \n§Ä¡v  _Ôs¸Smhp¶XmWv. 
tUm.Fkv.hn. [\y 
t]mÌp{KmPpthäv hn²ymÀ°n\n(Fw.Un.Fkv) 
Un¸mÀ«vsaâvHm v^HmdÂ  saUnkn³&tdUntbmfPn, 
{ioaqImw_nI C³Ìnäyq«v Hm^vsUâÂ  kb³kv, 
IpetiJcw þ 629 161. 
Mob 8531066480 
Email:drdhanyasv2009@gmail.com 
   
 
Øew:         {]Ya At\zjIsâH¸v 
 
XobXn :        ]s¦Sp¡p¶ BfnsâH¸v 
   
 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
PART 2 OF 2 
PARTICIPANTS CONSENT FORM 
 
The details of the study have been explained to me in writing and the 
details have been fully explained to me. I am aware that the results of the study may 
not be directly beneficial to me but will help in the advancement or medical 
sciences. I confirm that I have understood the study and had the opportunity to ask 
questions. I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without the medical care 
that will normally be provided by the hospital being affected. I agree not to restrict 
the use of any data or results that arise from this study provided such a use is only 
for scientific purpose(s). I have been given an information sheet giving details of the 
study. I fully consent to participate in the study titled “Comparison of Plasma 
Cotinine, Serum B12 and Serum Ferritin Levels between Smokers and Non smokers 
with Recurrent Aphthous Stomatitis   Versus Controls - A Cross sectional study”.  
Serial no / Reference no:       
Name of the participant: 
 
Address of the participant: 
 
Contact number of the participant: 
 
Signature / thumb impression of the participant / Legal guardian 
Witnesses:     
1. 
2. 
 
Date: 
Place: 
  
 
 
 
k½X]{Xw 
`mKw þ 2 
 
 Cu ]T\s¯ ]änbpÅFÃmImcy§fpw F\n¡v ]dªv a\Ênem¡nXcnIbpwAXnsâHcp ]IÀ¸v 
F\n¡p \ÂIpIbpwsNbvXn«p-v.  Cu ]T\w KthjW¯n\mbnDÅXmsW¶pw F\n¡vCXnÂ \n¶v  
t\cn«vHcp ^ehpwD-mInsÃ¶pw Rm³ a\Ênem¡p¶p.  Cu ]T\¯nsâcoXnbpwDt±ihpw F\n¡v  
a\Ênem¡nX¶n«p-v.  AXp t]mse  F\n¡vkwib§Ä tNmZn¡m³  Ahkc§Äe`n¨n«pap-v.  CXnÂ 
]s¦Sp¡m\pw  ]s¦Sp¡mXncn¡m\pw  DÅ AhImiw  F\n¡ps-¶pwAXpt]mse  ]T\¯nsâGXp 
L«¯nepwCXnÂ \n¶v ]n³h§m\pÅkzmX{´yhpw F\n¡ps-¶v  Rm³ a\Ênem¡p¶p. Cu ]T\¯nÂ 
]s¦Sp¡p¶XpsImt-m, ]s¦Sp¡m¯XpsImt-mFsâaäpNnInÕIsf _m[n¡p¶XsÃ¶v Rm³  
Andbp¶p.  
¹mkvam tIm«n³, kodwB12aäpw. kodw s]cnSn³Afhv, ]pIhen¡p¶hcptSbpw, 
]pIhen¡m¯hcptSbpwXmcXaywAXns\ 
d¡dâvB^vXkvtÌmssassS¸oSvF¶pwhmbvtcmKt¯mSvtNÀ¶pÅXmcXay ]T\w. F¶ KthjW¯nÂ 
]s¦Sp¡p¶Xn\pw CXnsâ ^e§Äimkv{XteJ\¯nÂ {]kn²oIcn¡p¶Xn\pw F\n¡v k½XamsW¶v 
Rm³ CXn\mÂAndbn¨psImÅp¶p.  
 
kocnbÂ \¼À / d^d³kv \¼À : 
]s¦Sp¡p¶ Bfnsâ t]cv : 
taÂhnemkw : 
t^m¬ \¼À :  
 
         H¸v / hnceSbmfw 
km£n :   
   
     
Øew : 
XobXn 
   
 
 
SREE MOOKAMBIKA INSTITUTE OF DENTAL SCIENCE 
DEPARTMENT OF ORAL MEDICINE AND RADIOLOGY 
“Comparison of Plasma Cotinine, Serum B12 and Serum Ferritin Levels between 
smokers and non-smokers with Recurrent Aphthous Stomatitis   Versus Controls – 
A Cross sectional study”.  
CASE SHEET PROFORMA FOR ASSESSING ORAL 
RECURRENT APHTHOUS ULCER PATIENTS 
OP NO 
NAME (Optional) 
AGE    :  ------------------ years 
SEX    :  Male / Female 
OCCUPATION:  
ADDRESS: 
SOCIOECONOMIC STATUS: 
 
CHIEF COMPLAINT- 
 
 
 
DENTAL HISTORY   - 
 
 
MEDICAL HISORY - 
FAMILY HISTORY: 
 
PERSONAL HISTORY: 
a. Smoking Habit: 
i. Duration - 
ii. Number of cigarettes per day - 
GENERAL EXAMINATION: 
Built Nourishment 
 
 
 
VITAL SIGNS: 
Pulse rate 
 
Respiratory rate 
 
Temperature 
 
BP 
 
 
LOCAL EXAMINATION 
HARD TISSUE EXAMINATION 
a. Oral hygiene- Good/Fair/Poor 
i. Soft Tissue Examination 
b. Recurrent Aphthous ulcer- 
i. Size 
ii. Number 
iii. Type 
c. Photographs: 
 
 
d. Other observations: 
 
PROVISIONAL DIAGNOSIS: 
 
DIFFERENTIAL DIAGNOSIS: 
 
INVESTIGATIONS: 
 
FINAL DIAGNOSIS: 
 
 
 
 
 
 
 
 
 
 
 
DATA SHEET 
 
Sl. No 
Group I/II/III/IV 
Plasma Cotinine Serum B12 Serum Ferritin 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF PLASMA COTININE, SERUM VIT.B12, AND SERUM 
FERRITIN LEVELS BETWEEN SMOKERS AND NONSMOKERS WITH 
RECURRENT APHTHOUS STOMATITIS- A CROSS SECTIONAL STUDY. 
 
GROUP No 
SERUM  
VIT.B12 
SERUM  
FERRITIN 
PLASMACOTININE 
 
NORMAL RANGE 
 
180-914 pg/ml 
M-23-336ng/ml 
F -11-307ng/ml 
0.0005 – 0.028 
ng/ml 
 
 
 
HEALTHY GROUP 
1 320 88.3 0.0015 
2 199 13.6 0.0136 
3 270 14.3 0.0067 
4 885 59.3 0.0282 
5 300 25.9 0.0141 
6 285 40.3 0.0002 
7 359 11.4 0.0002 
8 255 57 0.0243 
9 283 62 0.0083 
10 302 70 0.0022 
 
 
 
 
RECURRENT 
APTHOUS 
STOMATITIS 
1 103 102.8 0.0016 
2 287 11.3 0.0171 
3 504 30.3 0.0004 
4 266 5.7 0.00053 
5 404 15.9 0.0098 
6 346 17.5 0.00013 
7 290 16.0 0.00013 
8 280 18.0 0.00114 
9 320 29 0.00218 
10 502 33 0.00114 
 
 
 
 
 
SMOKERS WITHOUT 
RAS 
1 710 35.1 0.0294 
2 352 183.7 0.0212 
3 275 171.6 0.00425 
4 780 202 0.000425 
5 209 308 0.0007 
6 294 296 0.00037 
7 253 183 0.0007 
8 503 52 0.0005 
9 498 49 0.0222 
10 399 101 0.0198 
 
 
 
 
 
SMOKERS WITH RAS 
1 188 90.5 0.0003 
2 783 38.2 0.0022 
3 624 80.2 0.0011 
4 299 34.0 0.00032 
5 303 101 0.00028 
6 482 121 0.0012 
7 200 111 0.0022 
8 289 121 0.0012 
9 302 201 0.0022 
10 355 285 0.0024 
